<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">58204</article-id><article-id pub-id-type="doi">10.7554/eLife.58204</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-188604"><name><surname>Theard</surname><given-names>Patricia L</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-188605"><name><surname>Sheffels</surname><given-names>Erin</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-188606"><name><surname>Sealover</surname><given-names>Nancy E</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-188607"><name><surname>Linke</surname><given-names>Amanda J</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-188608"><name><surname>Pratico</surname><given-names>David J</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-184827"><name><surname>Kortum</surname><given-names>Robert L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1634-4882</contrib-id><email>robert.kortum@usuhs.edu</email><xref ref-type="aff" rid="aff1"/><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution>Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences</institution><addr-line><named-content content-type="city">Bethesda</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Corey</surname><given-names>Seth J</given-names></name><role>Reviewing Editor</role><aff><institution>Cleveland Clinic</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Cooper</surname><given-names>Jonathan A</given-names></name><role>Senior Editor</role><aff><institution>Fred Hutchinson Cancer Research Center</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>08</day><month>09</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>9</volume><elocation-id>e58204</elocation-id><history><date date-type="received" iso-8601-date="2020-04-23"><day>23</day><month>04</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-08-14"><day>14</day><month>08</month><year>2020</year></date></history><permissions><ali:free_to_read/><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><ali:license_ref>http://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0 public domain dedication</ext-link>.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-58204-v1.pdf"/><abstract><p>Drug treatment of 3D cancer spheroids more accurately reflects in vivo therapeutic responses compared to adherent culture studies. In EGFR-mutated lung adenocarcinoma, EGFR-TKIs show enhanced efficacy in spheroid cultures. Simultaneous inhibition of multiple parallel RTKs further enhances EGFR-TKI effectiveness. We show that the common RTK signaling intermediate SOS1 was required for 3D spheroid growth of EGFR-mutated NSCLC cells. Using two distinct measures of pharmacologic synergy, we demonstrated that SOS1 inhibition strongly synergized with EGFR-TKI treatment only in 3D spheroid cultures. Combined EGFR- and SOS1-inhibition markedly inhibited Raf/MEK/ERK and PI3K/AKT signaling. Finally, broad assessment of the pharmacologic landscape of drug-drug interactions downstream of mutated EGFR revealed synergy when combining an EGFR-TKI with inhibitors of proximal signaling intermediates SOS1 and SHP2, but not inhibitors of downstream RAS effector pathways. These data indicate that vertical inhibition of proximal EGFR signaling should be pursued as a potential therapy to treat EGFR-mutated tumors.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>Lung cancer is the leading cause of cancer-related deaths worldwide. In non-smokers, this disease is usually caused by a mutation in a protein found on the surface of a cell, called EGFR. In healthy lung cells, these proteins trigger a chain of chemical signals that tell the cells to multiply. However, faulty forms of EFGR make the cells grow uncontrollably, leading to the formation of tumors.</p><p>Current treatments use EGFR inhibitors that block the activity of these proteins. But cancer cells often become resistant to these treatments by activating other types of growth proteins. One way to overcome this resistance has been by targeting the signaling pathways within individual tumors. But since those pathways differ between tumors, it has been challenging to find a single therapy that can treat all drug-resistant cancer cells.</p><p>Now, Theard et al. assessed the therapeutic effects of blocking a specific protein inside lung cells, called SOS1, which is involved in growth signaling in all tumor cells. Six different types of human lung cancer cells were used, all of which had faulty forms of EGFR, with three of the cell types showing drug resistance to current therapies. The cancer cells were either exposed to EGFR inhibitors only or to a combination of EGFR and SOS1 inhibitors. The most effective treatment was found to be through combinational therapy, with enhanced killing of drug-resistant cells.</p><p>Theard et al. further assessed the effect of combinational therapy using cells kept in two different ways. Cancer cells were either grown in a two-dimensional format, with cells forming a single cell layer, or in a three-dimensional format, where cells were multi-layered and grew on top of each other as self-aggregating spheroids. Combinational therapy treatment was only successful when the cells where grown in a three-dimensional format.</p><p>These findings highlight that future drug development studies should give consideration to the way cells are grown, as it can impact the results. They also provide a steppingstone towards tackling drug resistance in lung cancers that arise from EGFR mutations.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>spheroids</kwd><kwd>son of sevenless</kwd><kwd>synergy</kwd><kwd>lung adenocarcinoma</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000090</institution-id><institution>Congressionally Directed Medical Research Programs</institution></institution-wrap></funding-source><award-id>LC160222</award-id><principal-award-recipient><name><surname>Kortum</surname><given-names>Robert L</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000090</institution-id><institution>Congressionally Directed Medical Research Programs</institution></institution-wrap></funding-source><award-id>LC180213</award-id><principal-award-recipient><name><surname>Kortum</surname><given-names>Robert L</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Combined EGFR and SOS1 inhibition synergize to inhibit NSCLC spheroid growth.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Lung cancer is the leading cause of cancer-related death worldwide; adenocarcinomas are the most common subtype of lung cancer. Oncogenic driver mutations in the RTK/RAS pathway are found in over 75% of lung adenocarcinomas (<xref ref-type="bibr" rid="bib2">Cancer Genome Atlas Research Network, 2014</xref>). Activating EGFR mutations occur in 10–30% of lung adenocarcinomas and are the major cause of lung cancer in never-smokers. In patients whose tumors harbor either an L858R mutation or an exon 19 deletion (85% of EGFR mutated tumors), first-generation EGFR-tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib enhance progression-free survival (<xref ref-type="bibr" rid="bib37">Mok et al., 2009</xref>; <xref ref-type="bibr" rid="bib64">Yang et al., 2017</xref>; <xref ref-type="bibr" rid="bib7">Eberhard et al., 2005</xref>). However, resistance to first generation EGFR-TKIs invariably occurs. In most cases, acquired resistance to first generation EGFR-TKIs occurs via either a secondary EGFR ‘gatekeeper mutation’ (T790M, 50–60% of cases) that renders the receptor insensitive to first generation EGFR-TKIs or oncogenic shift to alternative RTKs (15–30%). To treat patients with T790M-mutated resistant tumors, the third generation EGFR-TKI osimertinib, which selectively targets activating EGFR mutant proteins including T790M but spares wild-type EGFR, was developed (<xref ref-type="bibr" rid="bib23">Jänne et al., 2015</xref>; <xref ref-type="bibr" rid="bib3">Cross et al., 2014</xref>). However, despite further enhancing survival of patients with EGFR-mutant tumors, resistance again emerges.</p><p>Unlike first-generation EGFR-TKIs, mechanisms driving osimertinib resistance are more variable, including both EGFR-dependent (10–30%) and EGFR-independent mechanisms (<xref ref-type="bibr" rid="bib34">Mancini et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Romaniello et al., 2018</xref>; <xref ref-type="bibr" rid="bib31">La Monica et al., 2017</xref>; <xref ref-type="bibr" rid="bib8">Eberlein et al., 2015</xref>). The most common EGFR-independent resistance mechanisms involve reactivation of the RTK/RAS/effector pathway (<xref ref-type="bibr" rid="bib8">Eberlein et al., 2015</xref>), often via enhanced signaling through parallel RTKs (<xref ref-type="bibr" rid="bib34">Mancini et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Romaniello et al., 2018</xref>; <xref ref-type="bibr" rid="bib31">La Monica et al., 2017</xref>; <xref ref-type="bibr" rid="bib52">Shi et al., 2016</xref>; <xref ref-type="bibr" rid="bib42">Park et al., 2016</xref>; <xref ref-type="bibr" rid="bib28">Kim et al., 2019</xref>; <xref ref-type="bibr" rid="bib58">Taniguchi et al., 2019</xref>; <xref ref-type="bibr" rid="bib25">Jimbo et al., 2019</xref>; <xref ref-type="bibr" rid="bib39">Namba et al., 2019</xref>). Here, combining osimertinib with individual RTK inhibitors can both inhibit the development of resistance through the inhibited RTK and kill cancer cells with resistance driven by the specific RTK being inhibited. However, simultaneous inhibition of multiple RTKs with osimertinib may be required to eliminate oncogenic shift to alternative RTKs (<xref ref-type="bibr" rid="bib46">Romaniello et al., 2018</xref>). Downstream of RAS, co-targeting intermediates of the RAF/MEK/ERK and PI3K/AKT pathways enhances of osimertinib effectiveness, however, signaling through the uninhibited effector pathway may drive resistance (<xref ref-type="bibr" rid="bib59">Tricker et al., 2015</xref>; <xref ref-type="bibr" rid="bib20">Jacobsen et al., 2017</xref>; <xref ref-type="bibr" rid="bib29">Ku et al., 2018</xref>; <xref ref-type="bibr" rid="bib18">Ichihara et al., 2017</xref>). Thus, it may be important for therapeutic combinations including osimertinib to stifle all downstream RTK/RAS signaling to be effective.</p><p>Recent studies suggest that pharmacologic assessments of targeted therapeutics should be performed under 3D culture conditions rather than in 2D adherent cultures (<xref ref-type="bibr" rid="bib41">Nunes et al., 2019</xref>; <xref ref-type="bibr" rid="bib33">Langhans, 2018</xref>). 3D spheroids show altered growth characteristics, changes in cell surface proteins, altered metabolism, changes in activation of signaling pathways or altered responses to targeted pathway inhibitors, and are more resistant to drug-induced apoptosis compared to 2D adherent cultures signaling (<xref ref-type="bibr" rid="bib15">Hao et al., 2019</xref>; <xref ref-type="bibr" rid="bib27">Kim et al., 2011</xref>; <xref ref-type="bibr" rid="bib44">Riedl et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Jones et al., 2019</xref>). These differences may be particularly relevant in <italic>EGFR</italic>-mutated NSCLC. <italic>EGFR</italic>-mutated cells show differential RTK expression and phosphorylation in 3D versus 2D conditions (<xref ref-type="bibr" rid="bib9">Ekert et al., 2014</xref>). Further, EGFR-mutated cells respond more robustly to first-generation EGFR-TKIs in 3D cultures, and these responses more closely resemble responses seen in vivo (<xref ref-type="bibr" rid="bib19">Jacobi et al., 2017</xref>). These data highlight the need for pharmacologic assessment of therapeutics designed to treat <italic>EGFR</italic>-mutated NSCLC under 3D culture conditions.</p><p>The ubiquitously expressed RasGEFs (guanine nucleotide exchange factors) SOS1 and SOS2 (son of sevenless 1 and 2) are common signaling intermediates of RTK-mediated RAS activation. Although not initially considered as drug targets because of the low oncogenic potential of SOS (<xref ref-type="bibr" rid="bib61">Vigil et al., 2010</xref>), there has been renewed interest in SOS proteins as therapeutic targets for cancer treatment. We and others have shown that SOS1 and SOS2 may be important therapeutic targets in KRAS-mutated cancer cells (<xref ref-type="bibr" rid="bib24">Jeng et al., 2012</xref>; <xref ref-type="bibr" rid="bib50">Sheffels et al., 2018</xref>; <xref ref-type="bibr" rid="bib51">Sheffels et al., 2019</xref>), and a specific SOS1 inhibitor (BAY-293) has recently been identified (<xref ref-type="bibr" rid="bib16">Hillig et al., 2019</xref>). Here, we investigate SOS1 and SOS2 as potential therapeutic targets in EGFR-mutated lung adenocarcinoma cells. Using two distinct measures of pharmacologic synergy, we demonstrate that SOS1 inhibition using BAY-293 synergizes with osimertinib only under 3D spheroid culture conditions, and in doing so add to the growing evidence that pharmacologic assessment of novel therapeutics designed to treat cancer must be performed under 3D culture conditions (<xref ref-type="bibr" rid="bib9">Ekert et al., 2014</xref>; <xref ref-type="bibr" rid="bib50">Sheffels et al., 2018</xref>; <xref ref-type="bibr" rid="bib41">Nunes et al., 2019</xref>; <xref ref-type="bibr" rid="bib22">Janes et al., 2018</xref>; <xref ref-type="bibr" rid="bib19">Jacobi et al., 2017</xref>). By assessing the pharmacologic landscape of EGFR/RAS pathway inhibitors, we demonstrate that inhibition of proximal signaling is required to synergize with osimertinib, and that combined EGFR and SOS1 inhibition synergizes to inhibit RAS effector signaling in 3D culture. These findings have significant therapeutic implications for the development of combination therapies to treat EGFR-mutated lung adenocarcinoma.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>SOS1 deletion inhibits transformation in EGFR-mutated NSCLC cells</title><p>Previous studies showed that EGFR-mutated NSCLC cell lines show much more robust responsiveness to first-generation EGFR-TKIs in 3D culture (monoculture cancer cell line spheroids or monoculture or mixed culture organoids in ECM/Matrigel) compared to 2D adherent culture, and further that 3D conditions more readily mirror EGFR-TKI responses seen in vivo (<xref ref-type="bibr" rid="bib19">Jacobi et al., 2017</xref>). To confirm these findings and extend them to third-generation EGFR-TKIs, we assessed dose-dependent survival of both first-generation EGFR-TKI sensitive (HCC827, exon 19 deletion [Δ<italic>ex</italic>19]) or resistant (NCI-H1975, L858R/T790M) NSCLC cell lines to either gefitinib or osimertinib treatment under both adherent (2D) or spheroid (3D) culture conditions (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). HCC827 and H1975 cells were plated in either adherent or spheroid cultures, allowed to rest for 48 hr, and then treated with increasing doses of either the first-generation EGFR-TKI gefitinib or the third-generation EGFR-TKI osimertinib for 4 days. HCC827 cells showed responsiveness to both EGFR-TKIs under 2D and 3D culture conditions, however in both cases 3D spheroid cultures showed a &gt; 1 log enhancement in EGFR-TKI efficacy and enhanced overall growth inhibition. While NCI-H1975 cells were not sensitive to gefitinib, osimertinib treatment of H1975 cells showed enhanced efficacy and increased overall growth inhibition in 3D spheroids over 2D adherent cultures.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title><italic>SOS1</italic> deletion inhibits anchorage-dependent (3D) transformation in EGFR-mutated NSCLC cell lines.</title><p>(<bold>A</bold>) Dose-response curves of EGFR-mutated HCC827 (Δex19) (left) or NCI-H1975 (L858R/T790M) (right) cells treated with gefitinib or osimertinib under 2D anchorage-dependent (gray diamonds) or 3D spheroid (black squares) culture conditions. (<bold>B-C</bold>) 2D proliferation (left) or 3D spheroid growth (right) in pooled populations of (<bold>B</bold>) HCC827 or (<bold>C</bold>) NCI-H1975 cells where <italic>SOS1</italic> or <italic>SOS2</italic> has been deleted using CRISPR/Cas9 vs NT controls. 10x images of representative spheroids at day 0 and 21 are shown, scale bar = 250 mm. (<bold>D</bold>) 3D transformation in pooled populations of the indicated EGFR-mutated NSCLC cell lines where <italic>SOS1</italic> or <italic>SOS2</italic> has been deleted using CRISPR/Cas9 vs NT controls. (<bold>E</bold>) Dose-response curve cells of NCI-H1975 cells treated with the SOS1 inhibitor BAY-293 under 2D anchorage-dependent (gray diamonds) or 3D spheroid (black squares) culture conditions. Data are represented as cell # versus untreated for each individual cell line. (<bold>F</bold>) Dose-response curves of NCI-H1975 cells where <italic>SOS1</italic> (red circles) or <italic>SOS2</italic> (blue triangles) has been deleted using CRISPR/Cas9 vs NT controls (black squares) treated with BAY-293 under 3D spheroid culture conditions. For each condition, the untreated sample was set to 100%, and drug-treated samples were compared to untreated for each cell line. Dose-response curves and 2D proliferation are presented as mean +/- s.d. from a least three independent experiments. For transformation studies, data are from four independent experiments. Each individual experiment was performed using populations (not clones) of independently CRISPR’d cells. For each experiment, three technical replicates were assessed. Statistical significance was determined by ANOVA using Tukey’s method for multiple comparisons. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001 vs. NT cells. # p&lt;0.05, ##p&lt;0.01 vs. <italic>SOS1</italic> KO cells.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>The SOS1 inhibitor BAY-293 is specific for SOS1 and is enhanced by<italic>SOS2</italic>deletion in EGFR (T790M) mutated NSCLC cell lines.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58204-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58204-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Deletion of SOS1 using CRISPR/Cas9.</title><p>293 T cells were transduced with lentiviruses expressing Cas9 and either a non-targeting sgRNA (NT) or one of eight different sgRNAs targeting SOS1. Whole cell lysates (WCLs) were analyzed by western blotting with antibodies specific for SOS1 or β-actin. SOS1 sgRNA constructs #1, #2, and #8 consistently showed &gt;90% reduction in total SOS1 protein abundance. SOS1-2 was used for experiments in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58204-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>The SOS1 inhibitor BAY-293 is specific for SOS1 and is enhanced by <italic>SOS2</italic> deletion in EGFR (T790M) mutated NSCLC cell lines.</title><p>(<bold>A-C</bold>) Dose-response curves of NCI-H1975 (<bold>A</bold>), PC9-TM (<bold>B</bold>), or H3255-TM (<bold>C</bold>) cells where <italic>SOS1</italic> (red circles) or <italic>SOS2</italic> (blue triangles) has been deleted using CRISPR/Cas9 vs NT controls (black squares) treated with BAY-293 under 3D spheroid culture conditions. For each condition, the untreated sample was set to 100%, and drug-treated samples were compared to untreated for each cell line. Data are presented as mean +/- s.d. from at least three independent experiments. Data are represented as cell # versus untreated for each individual cell line. For each experiment, three technical replicates were assessed.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58204-fig1-figsupp2-v1.tif"/></fig></fig-group><p>SOS1 and SOS2 are ubiquitously expressed RasGEFs responsible for transmitting EGFR signaling to downstream effector pathways. To determine whether SOS1 or SOS2 were required for 2D anchorage-dependent proliferation or 3D spheroid growth in EGFR-mutated NSCLC cells, <italic>SOS1</italic> (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> and <xref ref-type="bibr" rid="bib38">Munoz et al., 2016</xref>) or <italic>SOS2</italic> (<italic>31</italic>) were deleted in pooled populations of HCC827 and H1975 cells to avoid clonal effects, and both proliferation and spheroid growth were assessed versus NT controls (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>). In adherent culture, neither <italic>SOS1</italic> nor <italic>SOS2</italic> deletion altered proliferation (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). In contrast, <italic>SOS1</italic> deletion completely inhibited spheroid growth in both HCC827 and H1975 cells, indicating that SOS1 was required to maintain the transformed phenotype in both cell lines. To determine whether SOS1 was generally required for mutant EGFR-driven transformation, we further deleted <italic>SOS1</italic> or <italic>SOS2</italic> in both first-generation sensitive NCI-H3255 (L858R) and PC9 (Δ<italic>ex</italic>19) cells and in subcultures of these cell lines that had acquired T790M mutations after continuous EGFR-TKI treatment (PC9-TM [<xref ref-type="bibr" rid="bib5">de Bruin et al., 2014</xref>] and H3255-TM [<xref ref-type="bibr" rid="bib10">Engelman et al., 2006</xref>]). In all cases, <italic>SOS1</italic> deletion significantly diminished oncogenic transformation, whereas <italic>SOS2</italic> deletion had variable effects on transformation depending on the EGFR mutated cell line examined (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). These data indicate that SOS1 is the major RasGEF responsible for oncogenesis downstream of mutated EGFR.</p><p>BAY-293 was recently described as a specific inhibitor for SOS1 (<xref ref-type="bibr" rid="bib16">Hillig et al., 2019</xref>). To determine whether SOS1 inhibition was similarly more effective in 3D spheroids over 2D adherent culture, we assessed dose-dependent survival of H1975 cells after BAY-293 treatment under both 2D and 3D culture conditions (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). Similar to what we observed after either EGFR-TKI treatment (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) or <italic>SOS1</italic> deletion (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>), BAY-293 showed enhanced efficacy and increased overall growth inhibition in 3D spheroids over 2D adherent cultures. To confirm the specificity of BAY-293 for SOS1, we further treated 3D spheroid cultured H1975, PC9-TM, and H3255-TM cells where either <italic>SOS1</italic> or <italic>SOS2</italic> had been deleted versus NT controls with increasing doses of BAY-293 for four days, and assessed cell viability within the spheroids using Cell Titre Glo (<xref ref-type="fig" rid="fig1">Figure 1F</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). BAY-293 treatment did not inhibit survival of spheroids where <italic>SOS1</italic> had been deleted, indicating the specificity of BAY-293 for SOS1. Further, cells where <italic>SOS2</italic> had been deleted showed an approximately 1-log enhancement in BAY-293 efficacy and enhanced overall growth inhibition compared to NT controls, indicating that SOS1 and SOS2 have some overlapping functions in supporting survival of spheroid cultured EGFR-mutated NSCLC cells. For these experiments, the untreated sample cell number at day four of treatment for each cell line (NT, <italic>SOS1</italic> KO, <italic>SOS2</italic> KO) was set to 100%, so differences in transformation (see <xref ref-type="fig" rid="fig1">Figure 1B–D</xref>) will not be appreciated. Further, for NCI-H1975 and NCI-H3255-TM cells, <italic>SOS1</italic> deletion does not show transformation differences after four days. Overall, these data suggest that EGFR-mutated NSCLC cells are more sensitive to either mutant EGFR or SOS1 inhibition in 3D spheroid culture compared to traditional 2D adherent conditions.</p></sec><sec id="s2-2"><title>SOS1 inhibition synergizes with EGFR-TKIs to inhibit cell survival under anchorage independent (3D) culture conditions</title><p>Previous studies reported that combining osimertinib with an alternative RTK inhibitor may inhibit or treat the development of resistance driven by that specific RTK (<xref ref-type="bibr" rid="bib34">Mancini et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Romaniello et al., 2018</xref>; <xref ref-type="bibr" rid="bib31">La Monica et al., 2017</xref>), whereas simultaneous inhibition of multiple parallel RTKs with osimertinib may be required to effectively potentiate osimertinib action (<xref ref-type="bibr" rid="bib46">Romaniello et al., 2018</xref>). Further, while many studies show enhanced drug activity in combination therapies versus osimertinib treatment alone, they do not assess whether the effects of the two-drug combinations are truly synergistic; synergistic interactions between therapeutics allow for maximization of the therapeutic effect while minimizing adverse events and may be required for effective therapeutic combinations with targeted agents (<xref ref-type="bibr" rid="bib45">Roell et al., 2017</xref>).</p><p>SOS1 is a common downstream mediator of RTK signaling. We hypothesized that SOS1 could be an effective drug target to synergize with EGFR-TKI inhibition to treat EGFR-mutated lung adenocarcinoma. To directly assess synergy between osimertinib and SOS1 inhibition, we use two distinct methods based on the most widely established reference models of drug additivity. The first method, isobologram analysis, assesses changes in the dose-response curves for mixtures of two drugs compared to sham mixtures of each individual drug with itself. The second method, Bliss independence analysis, assesses whether a mixture of two individual drug doses has a greater effect than would be expected if the two drugs acted independently. We will first describe and then use each method in turn to determine the whether SOS1 inhibition using BAY-293 could synergize with the EGFR-TKI osimertinib in <italic>EGFR</italic>-mutated lung adenocarcinoma cells.</p><p>Isobologram analysis is a dose-effect analysis based on the principle of Loewe additivity, which states that a drug mixed with itself, and by extension a mixture of two or more similar drugs, will show additive effects. For two drugs (Drug A and Drug B) that have parallel dose-response curves so that a constant potency ratio is maintained at all doses of A and B (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), treatment using any dose-equivalent (DEQ) mixture of Drugs A and B will show a similar effect to treatment with either Drug A or Drug B alone if the effects of the two drugs are additive. In contrast, if the two drugs show synergism, then the effect seen by treatment with DEQ mixtures of A and B will be greater than the effect for either drug alone. By generating dose-response curves for different DEQ mixtures of Drugs A and B (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), one can compare the EC<sub>50</sub> of each DEQ mixture to the EC<sub>50</sub> of Drug A or Drug B alone on an isobologram plot (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). The EC<sub>50</sub> of each individual drug is plotted as the x- or y-intercept, and the calculated contribution of each drug to the overall EC<sub>50</sub> for each DEQ mix is plotted as a single point (EC<sub>50,A</sub>, EC<sub>50,B</sub>) on the graph. If the EC<sub>50</sub> values for each DEQ mix fall along the straight line (isobole) that connects the individual drug EC<sub>50</sub> values, then the drug-drug interaction is additive. In contrast, points that fall above or below the isobole indicate antagonism or synergy. The extent to which two drugs interact can be further quantified from the EC<sub>50</sub> data as a combination index (CI) (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). A CI between 0.8 and 1.2 indicates the two drugs have additive effects when combined, a CI &lt;0.8 indicates synergy, and a CI &gt;1.2 indicates antagonism.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>SOS1 inhibition synergizes with the EGFR-TKI inhibitor osimertinib to inhibit cell survival under anchorage-independent (3D) culture conditions.</title><p>(<bold>A-D</bold>) Isobologram analysis examines drug-drug synergy by comparing dose equivalent (DEQ) mixtures of two drugs based on their EC<sub>50</sub> values to treatment with either drug alone (<bold>A and B</bold>). From the dose-response curves of the DEQ mixtures, plotting the fractional EC<sub>50</sub> for each drug in the combination (purple) relative to the individual drug EC<sub>50</sub> values (blue, red) on an isobologram plot (<bold>C</bold>) and calculation of the combination index (CI, <bold>D and E</bold>) allows assessment of drug-drug synergy. Additive effects occur on the dashed lines of the isobologram plot and have a CI 0.8–1.2 (gray box), whereas synergistic interactions fall below the dashed lines and have a CI &lt;0.8. (<bold>E</bold>) Isobologram plots and CI from dose-equivalent treatments of H1975 EGFR-mutated NSCLC cells treated with DEQ combinations of osimertinib and BAY-293. Isobologram and CI data are presented as mean +/- s.d. from three independent experiments. (<bold>F</bold>) Bliss additivity evaluates whether the overall effect of an individual drug combination (E<sub>A+B mix</sub>) is greater than should be expected for two drugs with independent effects on the overall population (E<sub>A</sub> + E<sub>B</sub> – E<sub>A</sub> * E<sub>B</sub>). (<bold>G</bold>) The Bliss Index compares the ratio of the expected effect to the actual effect. Synergistic interactions have a Bliss Index &lt; 0.85. (<bold>H</bold>) Excess over Bliss evaluates the magnitude of the difference between the actual and expected effects. Increasingly synergistic interactions show an excess over Bliss Index &gt; 0. (<bold>I</bold>) Heat map of H1975 cells treated with the indicated doses of osimertinib and/or BAY-293 grown in either 2D (adherent) culture conditions or as 3D spheroids. Green indicates more cells, red indicates fewer cells. EC<sub>50</sub> values for each individual drug are indicated by an *. (<bold>J</bold>) Heat map of Bliss Index assessing drug-drug synergy between osimertinib and BAY-293 at each dose combination from D. (<bold>K</bold>) Heat map of excess over Bliss assessing drug-drug synergy between osimertinib and BAY-293 at each dose combination from D. Bliss Index and excess-over Bliss are presented as the mean from three independent experiments. For each experiment, three technical replicates were assessed.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>SOS1 inhibition synergizes with the EGFR-TKI inhibitor osimertinib to inhibit cell survival under anchorage-independent (3D) culture conditions.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58204-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58204-fig2-v1.tif"/></fig><p>To assess drug-drug synergy between osimertinib and BAY-293 via isobologram analysis, NCI-H1975 cells were cultured under 2D adherent or 3D spheroid conditions for 48 hr, and were treated with varying DEQ combinations of osimertinib:BAY-293 (see <xref ref-type="fig" rid="fig2">Figure 2B</xref>) for four days. Cell viability data was assessed using CellTiter-Glo and EC<sub>50</sub> values from each DEQ mixture were used to generate isobologram plots and calculate combination indices (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). When cells were cultured under 2D conditions, osimertinib and BAY-293 showed additive effects, as DEQ EC<sub>50</sub> values fell on the isobole and CI values were between 0.8 and 1.2. In contrast, when cells were cultured as 3D spheroids, osimertinib and BAY-293 showed significant synergy, as DEQ EC<sub>50</sub> values were well below the isobole and CI &lt;0.8.</p><p>Bliss independence analysis is an effect-based analysis based on the principle of Bliss additivity, which assumes that two drugs will act independently of each other so that their combined effect can be assessed by assessing the effect of each drug sequentially (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). Unlike isobologram analysis, this method does not require that two drugs being assessed have parallel dose-response curves and can be calculated based as few as three drug treatments, the effect each drug has on its own on the cell population, and the effect of combining the two drug treatments together. By representing the effect of each drug treatment as a probabilistic outcome between 0 (no effect) and 1 (100% effect), we can compare the observed effect of the drug-drug combination to the expected effect if each drug acted independently (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). The ratio of the expected effect to the observed effect is the Bliss Index (BI), where a BI &lt;1 indicates synergy (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). Alternatively, the magnitude of the difference between the observed and expected result can be reported as the excess over Bliss (<xref ref-type="fig" rid="fig2">Figure 2H</xref>). While excess over Bliss is the most widely reported synergy metric, the Bliss Index can be directly compared with the combination index in isobologram experiments and should be used when both synergy methods are used to assess a given drug-drug interaction.</p><p>To assess drug-drug synergy between osimertinib and BAY-293 via Bliss Independence analysis, NCI-H1975 cells were cultured under 2D adherent or 3D spheroid conditions for 48 hr and were treated with increasing doses of BAY-293, osimertinib, or combinations of the two drugs over a 3-log scale for four days. Cell viability was determined using CellTiter-Glo and overall viability (<xref ref-type="fig" rid="fig2">Figure 2I</xref>), Bliss index (<xref ref-type="fig" rid="fig2">Figure 2J</xref>), and excess over Bliss (<xref ref-type="fig" rid="fig2">Figure 2K</xref>) were represented as heat-maps. Similar to what we observed for isobologram analysis, osimertinib and BAY-293 did not show significant synergy in cells cultured under 2D adherent conditions. In contrast, we observed significant synergy between osimertinib and BAY-293, mostly at dose combinations of osimertinib and BAY-293 falling just below the individual drug EC<sub>50</sub> values. Overall, the data presented in <xref ref-type="fig" rid="fig2">Figure 2</xref> indicate that osimertinib and BAY-293 show significant drug-drug synergy in EGFR-mutated H1975 cells, but only in 3D spheroid culture conditions.</p><p>To determine whether the SOS1 inhibitor BAY-293 could generally synergize with EGFR-TKIs in EGFR-mutated lung adenocarcinoma cells, we extended our assessment of drug-drug synergy to isobologram analysis (<xref ref-type="fig" rid="fig3">Figure 3</xref>) and Bliss independence analysis (<xref ref-type="fig" rid="fig4">Figure 4</xref>) in six different EGFR-mutated lung adenocarcinoma cell lines. In cells that were sensitive to first-generation EGFR-TKIs (HCC827, PC9, H3255; T790 wild-type), we assess drug-drug synergy between BAY-293 and either a first-generation (gefitinib) or third-generation (osimertinib) EGFR-TKI. In cells that were resistant to first-generation EGFR-TKIs (H1975; PC9-TM, H3255-TM; T790M) we limited our assessment to synergy between BAY-293 and osimertinib. To first determine the individual EC<sub>50</sub> values for gefitinib, osimertinib, and BAY-293 in each cell line, cells were cultured as 3D spheroids for 48–72 hr, and then treated with increasing doses of drug for four days followed by assessment of cell viability by CellTiter-Glo (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). In five of six cell lines, the individual dose-response curves for BAY-293, osimertinib, and gefitinib (where appropriate) showed similar maximal effects and Hill coefficients, and were thus appropriate for linear isobologram analysis for each two-drug combination of BAY-293, osimertinib, and gefitinib (<xref ref-type="bibr" rid="bib57">Tallarida, 2011</xref>). In contrast, H3255-TM cells were only moderately sensitive to osimertinib, showing at most a 50% reduction in viability at high doses. Therefore, we limited our assessment of drug-drug synergy in H3255-TM cells to Bliss independence analysis. Further, to simplify our assessment of Bliss independence across multiple drugs and cell lines, we limited our drug treatments to 1:2, 1:1, and 2:1 mixtures of each drug combination based on dose equivalence (see <xref ref-type="fig" rid="fig4">Figure 4A</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Isobologram analysis showing that SOS1 inhibition synergizes with EGFR-TKI treatment to inhibit survival in multiple EGFR-mutated NSCLC cell lines.</title><p>Isobologram analysis and Combination Index (CI) from dose-equivalent treatments of the indicated EGFR-mutated gefitinib-sensitive (L858R or Δex19, top) or gefitinib-resistant (T790M, bottom) NSCLC cell lines with combinations of gefitinib, osimertinib, and BAY-293. Additive effects occur on the dashed lines of the isobologram plot and have a CI 0.8–1.2 (gray box), whereas synergistic interactions fall below the dashed lines and have a CI &lt;0.8. Data are presented as mean +/- s.d. from three independent experiments. For each experiment, three technical replicates were assessed.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>EGFR mutated NSCLC cell lines are responsive to osimertinib, BAY-293, and gefitinib in 3D spheroid cultures.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58204-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58204-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>EGFR mutated NSCLC cell lines are responsive to osimertinib, BAY-293, and gefitinib in 3D spheroid cultures.</title><p>(<bold>A-F</bold>) Dose-response curves of 3D spheroid cultured HCC827 (<bold>A</bold>), NCI-H1975 (<bold>B</bold>), PC9 (<bold>C</bold>), PC9-TM (<bold>D</bold>), H3255 (<bold>E</bold>), or H3255-TM (<bold>F</bold>) cells to osimertinib (black squares), BAY-293 (red circles) or gefitinib (grey diamonds). Hill coefficients +/- s.d. are shown to the right. Data are presented as mean +/- s.d. from at least three independent experiments. For each experiment, three technical replicates were assessed.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58204-fig3-figsupp1-v1.tif"/></fig></fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Bliss Independence analysis showing that SOS1 inhibition synergizes with EGFR-TKI treatment to inhibit survival in multiple EGFR-mutated NSCLC cell lines.</title><p>(<bold>A</bold>) Bliss Index heatmap from 3D spheroid cultured NCI-H1975 cells <xref ref-type="fig" rid="fig2">Figure 2A</xref> (left) and horizontal projections of Bliss Indices of drug treatments at 2:1, 1:1, and 1:2 ratios of osimertinib:BAY-293 based on dose equivalencies (right). Increasingly synergistic interactions (Bliss index &lt;0.85) are indicated by the corresponding heat map. The concentration of BAY-293 (held constant, bottom) and of osimertinib (above each horizontal projection) are given. The IC<sub>50</sub> for each individual drug are shown (*). (<bold>B</bold>) Bliss Index heatmaps based on A for the indicated gefitinib-sensitive and gefitinib-resistant cell lines at 2:1, 1:1, and 1:2 ratios of osimertinib, gefitinib, and BAY-293 based on dose equivalencies. Data for NCI-H1975 cells are the same as in A. Data are presented as the mean from three independent experiments. For each experiment, three technical replicates were assessed.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Bliss Independence analysis showing that SOS1 inhibition synergizes with EGFR-TKI treatment to inhibit survival in multiple EGFR-mutated NSCLC cell lines.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58204-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58204-fig4-v1.tif"/></fig><p>For each first-generation EGFR-TKI sensitive cell line (HCC827, PC9, H3255), gefitinib and osimertinib did not show any synergy with each other by either isobologram analysis (<xref ref-type="fig" rid="fig3">Figure 3</xref>) or Bliss Independence analysis (<xref ref-type="fig" rid="fig4">Figure 4</xref>), instead showing additive effects (CI and BI ~1) as would be expected for two drugs with the same molecular target. In contrast, BAY-293 showed significant synergy with gefitinib and osimertinib by both isobologram analysis (<xref ref-type="fig" rid="fig3">Figure 3</xref>) and Bliss Independence analysis (<xref ref-type="fig" rid="fig4">Figure 4</xref>), suggesting that SOS1 inhibition can act as a secondary treatment for all EGFR-TKIs. Further, in all three T790M mutated cell lines (H1975, PC9-TM, H3255-TM), BAY-293 again showed synergy with osimertinib. These data suggest that combined SOS1 and EGFR inhibition is a robust therapeutic combination that synergize to inhibit EGFR-mutated lung adenocarcinoma cell growth.</p></sec><sec id="s2-3"><title>Synergy between BAY-293 and osimertinib is independent of SOS2</title><p>We showed that <italic>SOS2</italic> deletion sensitized NCI-H1975 cells to the SOS1 inhibitor BAY-293 (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). We wanted to determine whether the synergy we observed between EGFR- and SOS1-inhibition (<xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig4">4</xref>) was enhanced by <italic>SOS2</italic> deletion in EGFR-mutated NSCLC cell lines. To examine whether SOS2 deletion alters the synergy between osimertinib and BAY-293 in EGFR (T790M) mutated cells, SOS2 was deleted in H1975, PC9-TM, and H3255-TM cells. For H1975 and PC9-TM cells, <italic>SOS2</italic> KO cells vs NT controls were cultured under 3D spheroid conditions for 48–72 hr, and were then treated with varying DEQ combinations of osimertinib:BAY-293 for 4 days. Cell viability data was assessed using CellTiter-Glo and EC<sub>50</sub> values from each DEQ mixture were used to generate Isobologram plots and calculate confidence intervals (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>). For both cell lines, <italic>SOS2</italic> deletion sensitized cells to BAY-293, decreasing EC<sub>50</sub> by 5–10-fold compared to NT controls without altering the EC<sub>50</sub> to osimertinib treatment alone. However, unlike what we observed in the NT control cells, osimertinib and BAY-293 showed only mild synergy in EGFR-mutated cells where <italic>SOS2</italic> was deleted as assessed by the distance of the interaction points to the isobole and the increased combination index vs. NT controls. Further, when we overlaid the NT and <italic>SOS2</italic> KO isobologram plots at two different scales of BAY-293, the drug combination data points were overlapping between NT and <italic>SOS2</italic> KO cells, suggesting that <italic>SOS2</italic> deletion did not enhance synergy between osimertinib and BAY-293.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title><italic>SOS2</italic> deletion does not enhance the synergistic interaction between SOS1 inhibition and EGFR-TKI treatment.</title><p>(<bold>A-B</bold>) Isobologram analysis (left) and Combination Index (right) from dose-equivalent treatments of osimertinib and BAY-293 in H1975 (<bold>A</bold>) or PC9-TM (<bold>B</bold>) cells where <italic>SOS2</italic> has been deleted (blue) versus NT controls (black). Overlay plots on two different BAY-293 dosing scales are shown below the individual isobologram plots. Additive effects occur on the dashed lines of the isobologram plot and have a CI 0.8–1.2 (gray box), whereas synergistic interactions fall below the dashed lines and have a CI &lt;0.8. (<bold>C</bold>) Bliss Index heatmaps for H3255-TM cells where <italic>SOS2</italic> has been deleted versus NT controls treated at at 1:2, 1:1, and 2:1 ratios of osimertinib and BAY-293 based on dose equivalencies. Data are presented as mean +/- s.d. from three independent experiments. For each experiment, three technical replicates were assessed.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title><italic>SOS2 </italic>deletion does not enhance the synergistic interaction between SOS1 inhibition and EGFR-TKI treatment.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58204-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58204-fig5-v1.tif"/></fig><p>Since H3255-TM cells are not appropriate for linear isobologram analysis between BAY-293 and osimertinib, we instead performed Bliss independence analysis to assess potential synergy between osimertinib and BAY-293 in the presence or absence of SOS2. H3255-TM cells where <italic>SOS2</italic> had been deleted vs NT controls were cultured under 3D spheroid conditions for 48–72 hr, and were then treated with increasing doses of osimertinib alone, BAY-293 alone, or mixtures of each drug dose at 1:2, 1:1, and 2:1 mixtures of osimertinib and BAY-293 based on dose equivalence for four days. Cell viability data was assessed using CellTiter-Glo, and the Bliss index was calculated for each drug mixture as shown in <xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="fig" rid="fig4">Figure 4</xref>. As was the case in H1975 and PC9-TM cells, while the <italic>SOS2</italic> deletion sensitized H3255-TM cells to BAY-293 we observed less overall synergy between osimertinib and BAY-293 H3255-TM cells where we had deleted <italic>SOS2</italic> vs NT controls. These data suggest that although osimertinib and BAY-293 synergize to limit viability of EGFR-mutated lung adenocarcinoma cells, the synergy between osimertinib and BAY-293 is independent of SOS2.</p></sec><sec id="s2-4"><title>BAY-293 and osimertinib synergize to inhibit RAS effector signaling</title><p>Mutated EGFR signals through downstream RAF/MEK/ERK and PI3K/AKT effector pathways to promote proliferation, transformation, and survival. Since <italic>SOS2</italic> deletion did not further enhance synergy between BAY-293 and osimertinib, we hypothesized that SOS1 inhibition specifically enhanced EGFR-TKI-dependent inhibition of downstream signaling in 3D culture. To perform signaling experiments on 3D cultured spheroids, cells were seeded in 24-well micropatterned low-attachment culture plates (Aggrewell, StemCell) containing ~1200 individual spheroids per condition. To determine the extent to which SOS1 inhibition and/or <italic>SOS2</italic> deletion altered osimertinib-dependent inhibition of downstream effector signaling in 3D culture, H1975 or PC9-TM cells where <italic>SOS2</italic> was deleted vs. NT controls were cultured as spheroids for 48–72 hr and then treated with increasing doses of osimertinib +/- BAY-293 prior to spheroid collection, lysis, and western blotting for phosphorylated ERK and AKT (<xref ref-type="fig" rid="fig6">Figure 6</xref>). In both NT and <italic>SOS2</italic> knockout cells, BAY-293 reduced the dose of osimertinib required to inhibit both ERK and AKT phosphorylation (<xref ref-type="fig" rid="fig6">Figure 6</xref>). For Raf/MEK/ERK signaling, Bliss Independence analysis of pERK quantitation revealed that either SOS1 inhibition or <italic>SOS2</italic> deletion independently synergized with osimertinib to inhibit Raf/MEK/ERK signaling, and the combination of inhibiting SOS1/2 signaling further enhanced this synergy. In contrast, for PI3K/AKT signaling <italic>SOS2</italic> deletion did not enhance the synergy between osimertinib and BAY-293. While either osimertinib treatment or <italic>SOS2</italic> deletion independently synergized with BAY-293 to inhibit AKT phosphorylation, <italic>SOS2</italic> deletion did not further enhance the ability osimertinib to inhibit PI3K/AKT signaling in the presence or absence of BAY-293. These data strongly suggest that vertical inhibition of EGFR and SOS1 limits call viability by inhibiting activation of both RAF/MEK/ERK and PI3K/AKT effector pathways.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>SOS1 inhibition synergizes with mutant EGFR inhibition to inhibit downstream effector signaling.</title><p>Western blots (<bold>A, D</bold>), pERK and pAKT quantitation (<bold>B, E</bold>), and Bliss Indices (<bold>C, F</bold>) of WCLs of NCI-H1975 cells (<bold>A-C</bold>, top) or PC9-TM cells (<bold>D-F</bold>, bottom) cultured under 3D spheroid conditions for 48 hr and then treated with the indicated concentrations of the EGFR-TKI osimertinib and/or the SOS1 inhibitor BAY-293 for 6 hr. Western blots are for pEGFR, EGFR, pAKT, AKT, pERK1/2, ERK1/2, HSP90, and β-actin. pERK and pAKT quantifications were calculated using a weighted average of total protein western blots. Combination Indices are based on pERK/Total protein and pAKT/Total protein quantitations. Increasingly synergistic combinations are indicated in yellow, orange, red, or purple. Phosphoprotein quantitations are presented as mean +/- s.d. from three independent experiments. Bliss indices are presented as mean from three independent experiments. For each experiment, three technical replicates were assessed.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>SOS1 inhibition synergizes with mutant EGFR inhibition to inhibit downstream effector signaling.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58204-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58204-fig6-v1.tif"/></fig></sec><sec id="s2-5"><title>Assessment of inhibitor landscape in EGFR-mutated cells lines shows synergy upon inhibition of upstream pathway effectors</title><p>Since the most common EGFR-independent resistance mechanisms involve reactivation of RTK/RAS/effector pathways (<xref ref-type="bibr" rid="bib34">Mancini et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Romaniello et al., 2018</xref>; <xref ref-type="bibr" rid="bib31">La Monica et al., 2017</xref>; <xref ref-type="bibr" rid="bib8">Eberlein et al., 2015</xref>), we wanted to assess whether inhibition of different proteins within the EGFR/RAS signaling pathway could synergize to inhibit 3D survival of EGFR (T790M) mutated cancer cells. To determine drug-drug synergies after inhibition of EGFR-RAS pathway signaling at different levels, we assessed synergy between osimertinib, inhibitors of EGFR signaling intermediates upstream of RAS (BAY-293 for SOS1 and RMC-4450 for SHP2), and inhibitors of the Raf/MEK/ERK (trametinib) and PI3K/AKT (buparlisib) pathways (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). H1975 and PC9-TM cells were treated with each individual inhibitor or 1:1 DEQ mixtures of every drug-drug combination, and the combination index was calculated to assess drug-drug synergy. Since H3255-TM cells are not suitable for isobologram analysis, these cells were treated with full-dose mixtures based on dose equivalence and the Bliss Index was calculated for each drug-drug combination (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). Intriguingly, all three cell lines showed drug-drug synergy with any combination of EGFR, SOS1, and SHP2 inhibition. In contrast, inhibition of downstream Raf/MEK/ERK or PI3K/AKT pathways failed to consistently synergize with either osimertinib or any other inhibitor (<xref ref-type="fig" rid="fig7">Figure 7B</xref>, top). These data support the premise that combined vertical inhibition of proximal EGFR signaling may constitute an effective strategy to treat EGFR-mutated lung adenocarcinomas.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Assessment of the EGFR/RAS pathway ‘inhibitor landscape’ suggests that combination therapies inhibiting mutated EGFR, SOS1, and SHP2 have therapeutic potential in EGFR-mutated NSCLC.</title><p>(<bold>A</bold>) Signaling diagram showing EGFR/RAS pathway inhibitors that were assessed for pairwise synergy by isobologram analysis using 50:50 dose-equivalent mixes of each drug pair. (<bold>B</bold>) Heat map of Combination Indices from isobologram analyses of the indicated drug-drug combinations in NT and <italic>SOS2</italic> KO NSCLC cell lines. Synergistic combinations are indicated in yellow, orange, or red. Data are presented as the mean from three independent experiments. (<bold>C-D</bold>) Isobologram analysis and Combination Index (CI) from dose-equivalent treatments of 3D spheroid cultured NCI-H1975 cells treated with the indicated two-drug (C) or three-drug (<bold>D</bold>) combinations of osimertinib (black), RMC-4550 (purple), and BAY-293 (red). For three drug combination, the two drugs indicated on the y-axis were held at a 1:1 ratio, and then mixed at dose equivalent ratiow with the third drug. CI values indicate enhanced synergy beyond the two drug combination on the y-axis of the isobologram plot and are calculated based on the y-axis drug combination calculated a s single drug treatment. Additive effects occur on the dashed lines of the isobologram plot and have a CI 0.8–1.2 (gray box), whereas synergistic interactions fall below the dashed lines and have a CI &lt;0.8. (<bold>E</bold>) Combination indices from two-drug combinations of osimertinib (black), RMC-4550 (purple), and BAY-293 (red) mixed at 2:1, 1:1, or 1:2 ratios or the three drug combination at a 1:1:1 ratio (grey). CI are calculated based on three individual drug treatments. (<bold>F</bold>) Signaling model based on data from Figures 1–7 showing that combined targeting of mutated EGFR and SOS1 provides sufficient vertical inhibition of upstream signaling to inhibit RAS effector signaling and block oncogenic transformation. This synergistic inhibition can be further enhanced by SHP2 inhibition, providing multiple potential drug combinations for therapeutic intervention in EGFR-mutated NSCLC. Isobologram and CI data are presented as mean +/- s.d. from three independent experiments. For each experiment, three technical replicates were assessed.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Assessment of the EGFR/RAS pathway ‘inhibitor landscape’ suggests that combination therapies inhibiting mutated EGFR, SOS1, and SHP2 have therapeutic potential in EGFR-mutated NSCLC.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58204-fig7-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-58204-fig7-v1.tif"/></fig><p>SHP2 is important for the stabilization of the GRB2:SOS1/2 complexes on EGFR (<xref ref-type="bibr" rid="bib4">Dance et al., 2008</xref>), and the mechanism of allosteric SHP2 inhibitors depends on SOS1 (<xref ref-type="bibr" rid="bib40">Nichols et al., 2018</xref>), although the contribution of SOS2 to SHP2 inhibitors was not assessed. To determine whether <italic>SOS2</italic> deletion altered the spectrum of drug-drug synergies in EGFR-mutated cells, parallel studies were performed in EGFR-mutated cells where <italic>SOS2</italic> was deleted (<xref ref-type="fig" rid="fig7">Figure 7B</xref>, bottom). Unlike what we observed for synergy between EGFR- and SOS1 inhibition, synergy between SOS1 and SHP2 inhibition was enhanced by <italic>SOS2</italic> deletion. These data suggest that SOS2 plays a role in SHP2-dependent signaling. SOS1 inhibition also synergized with MEK inhibition in <italic>SOS2</italic> KO cells. Given the strong synergy between SOS1 inhibition and <italic>SOS2</italic> deletion in inhibiting Raf/MEK/ERK signaling (<xref ref-type="fig" rid="fig6">Figure 6</xref>), these data suggest that deep inhibition of MEK signaling is sufficient to inhibit survival in EGFR-mutated cells.</p><p>To further evaluate synergy between inhibitors of proximal EGFR signaling, we examined combinations of EGFR- SOS1- and SHP2 inhibition both by expanded evaluation of each two-drug combination and by assessing whether combined inhibition of EGFR, SOS1, and SHP2 would be more effective than two drug combinations of these inhibitors. To assess each two-drug combination, H1975 cells cultured under 3D spheroid conditions were treated with dose-equivalent combinations of osimertinib, BAY-293, and RMC-4550, assessed for cell viability, and subjected to isobologram analysis to assess drug-drug synergy. Each two-drug combination showed synergy at three different DEQ ratios (<xref ref-type="fig" rid="fig7">Figure 7C</xref>), suggesting that inhibition of any two proximal signaling proteins may be an effective therapeutic regimen to treat EGFR-mutated cancer. To assess whether adding a third proximal inhibitor to each two-drug combination would further enhance synergistic inhibition of spheroid survival, each two-drug combination was mixed at 1:1 ratio, and then a third proximal pathway inhibitor was added to give the indicated three-drug mixtures (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). Isobologram analysis of these three drug mixtures revealed that addition of a third proximal pathway inhibitor to any two-drug combination of osimertinib, BAY-293, and RMC-4550 further enhanced synergy above what was observed for each two-drug combination (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). Finally, comparing the combination index for the three-drug combination at a 1:1:1 ratio when each drug is treated independently versus the two-drug combinations showed marked synergy for the three drug combination, but that this synergy was not significantly enhanced compared to the combination of osimertinib and BAY-293 (<xref ref-type="fig" rid="fig7">Figure 7E</xref>). These data indicate that vertical inhibition of proximal EGFR signaling with the combination of osimertinib and a SOS1 inhibitor may be the most the most effective therapeutic combination to treat <italic>EGFR</italic>-mutated NSCLC.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Activating <italic>EGFR</italic> mutations are found in 10–30% of lung adenocarcinomas and are the major cause of lung cancer in never smokers. The third-generation EGFR-TKI osimertinib enhances both progression-free (<xref ref-type="bibr" rid="bib56">Soria et al., 2018</xref>) and overall survival (<xref ref-type="bibr" rid="bib43">Ramalingam et al., 2020</xref>) compared to first generation EGFR-TKIs and is now considered first-line treatment in EGFR-mutated NSCLC. Osimertinib resistance often develops via activation of parallel RTK pathways (<xref ref-type="bibr" rid="bib34">Mancini et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Romaniello et al., 2018</xref>; <xref ref-type="bibr" rid="bib31">La Monica et al., 2017</xref>), and broad inhibition RTK signaling may enhance osimertinib efficacy and delay therapeutic resistance. Here, we demonstrate that inhibition of the common RTK signaling intermediate SOS1 using BAY-293 showed marked synergy with osimertinib in 3D spheroid-cultured EGFR-mutated NSCLC cells. Our observations that (i) osimertinib–BAY-293 synergy was only observed in 3D spheroids but not in adherent (2D) cultures and (ii) synergy between RTK-signaling intermediates and osimertinib was not broadly applicable to EGFR downstream signaling components but was limited to proteins upstream of RAS reveal novel insights into pharmacologic studies assessing therapeutics designed to treat NSCLC.</p><p>While most studies designed to identify or test therapeutic targets to treat cancer are done in 2D adherent culture, a growing body of evidence suggests that pharmacologic assessment of novel therapeutics must be performed in 3D culture systems (<xref ref-type="bibr" rid="bib41">Nunes et al., 2019</xref>). Here, there are many different 3D model systems available that vary in both ease-of-use and complexity of the system. The simplest systems employ non-scaffold-dependent monoculture of cancer cell lines where spheroids are either generated using hanging-drop methodology, magnetic levitation, or using ultra-low attachment plates. More complex systems include embedding spheroids in an extracellular matrix (Matrigel, collagen, gelatin, or a synthetic hydrogel) either as a cancer cell line monoculture or in combination with cancer-derived fibroblasts, or using specialized microfluidics or culturing cancer-derived organoids. These methods are have been thoroughly reviewed elsewhere (<xref ref-type="bibr" rid="bib33">Langhans, 2018</xref>). In the current study, we use ultra-low attachment plates of monoculture NSCLC cell lines as these have the advantage of recapitulating in vivo findings while allowing for dose-response studies done at scale (<xref ref-type="bibr" rid="bib36">Mittler et al., 2017</xref>).</p><p>In NSCLC, multiple studies have now revealed the importance of 3D culture systems in order to recapitulate in vivo findings. <italic>EGFR</italic>-mutated cells show differential RTK expression and phosphorylation in 3D versus 2D conditions (<xref ref-type="bibr" rid="bib9">Ekert et al., 2014</xref>) and respond more robustly to EGFR-TKIs in 3D cultures compared to 2D settings (<xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="bibr" rid="bib19">Jacobi et al., 2017</xref>); KRAS-mutated cell lines deemed ‘KRAS-independent’ in 2D culture (<xref ref-type="bibr" rid="bib1">Balbin et al., 2013</xref>; <xref ref-type="bibr" rid="bib54">Singh et al., 2009</xref>; <xref ref-type="bibr" rid="bib55">Singh et al., 2012</xref>; <xref ref-type="bibr" rid="bib49">Scholl et al., 2009</xref>; <xref ref-type="bibr" rid="bib32">Lamba et al., 2014</xref>) still require KRAS for anchorage-independent growth (<xref ref-type="bibr" rid="bib13">Fujita-Sato et al., 2015</xref>; <xref ref-type="bibr" rid="bib47">Rotem et al., 2015</xref>; <xref ref-type="bibr" rid="bib65">Zhang et al., 2006</xref>; <xref ref-type="bibr" rid="bib35">McCormick, 2015</xref>), and some KRAS<sup>G12C</sup>-mutated NSCLC cell lines respond to KRAS(G12C) inhibitors in 3D culture and in vivo but not in 2D adherent culture (<xref ref-type="bibr" rid="bib22">Janes et al., 2018</xref>). The relevance of 3D culture systems extends to the identification of novel therapeutic targets and therapeutic combinations. We recently showed that SOS2 is specifically required for PI3K-dependent protection from anoikis in KRAS-mutated NSCLC cells (<xref ref-type="bibr" rid="bib51">Sheffels et al., 2019</xref>) and <italic>SOS2</italic> deletion synergizes with MEK inhibition to kill <italic>KRAS</italic> mutated cells only under 3D culture conditions (<xref ref-type="bibr" rid="bib50">Sheffels et al., 2018</xref>). Here, we show marked synergy between vertical inhibition of EGFR and SOS1 in <italic>EGFR</italic> mutated cancer cells, but only under 3D culture conditions (<xref ref-type="fig" rid="fig2">Figure 2</xref>). CRISPR screens performed in spheroid cultures of KRAS- and EGFR-mutated NSCLC cell lines more accurately reproduce in vivo findings and identify drivers of oncogenic growth compared to screens performed in 2D cultures (<xref ref-type="bibr" rid="bib14">Han et al., 2020</xref>). Intriguingly, in this study SOS1 was essential for 3D spheroid survival but not 2D spheroid growth of both EGFR- and KRAS-mutated cells, and a recently accepted publication assessing a novel SOS1 inhibitor showed that it was more effective in 3D compared to 2D culture (<xref ref-type="bibr" rid="bib17">Hofmann et al., 2020</xref>). These data are in complete agreement with our data from <xref ref-type="fig" rid="fig1">Figure 1</xref> showing the requirement for SOS1 in 3D transformation but not 2D proliferation, and support our conclusion that SOS1 is an important therapeutic target in <italic>EGFR</italic>-mutated NSCLC. We hypothesize the requirement for SOS1 (and SOS2) to promote oncogenic growth in 3D versus proliferation in 2D culture are due to the requirement for PI3K signaling to promote cell survival in 3D but not 2D. Downstream of EGFR activation, the threshold for Raf/MEK/ERK versus PI3K/AKT pathway activation are drastically different, so small amounts of EFGR signaling (in the presence of either SOS1 or SOS2) promote Raf/MEK/ERK signaling, whereas high levels of EGFR signaling are required to activate the PI3K/AKT pathway (<xref ref-type="bibr" rid="bib12">Fortian and Sorkin, 2014</xref>). While this hypothesis remains to be tested, we speculate that depending on the specific oncogenic contexts, either SOS1 or SOS2 inhibition will be sufficient to modulate RTK signaling and change the threshold for PI3K signaling, thereby affecting oncogenic growth. These data suggest that future studies assessing novel therapeutics to treat lung adenocarcinomas must be performed in a 3D setting, and that SOS1 and SOS2 might be ubiquitous therapeutic targets in RTK-driven tumors.</p><p>Osimertinib resistant can occur via oncogenic shift to alternative RTKs including c-MET (<xref ref-type="bibr" rid="bib52">Shi et al., 2016</xref>), HER2 and/or HER3 (<xref ref-type="bibr" rid="bib34">Mancini et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Romaniello et al., 2018</xref>; <xref ref-type="bibr" rid="bib31">La Monica et al., 2017</xref>), IGF1R (<xref ref-type="bibr" rid="bib42">Park et al., 2016</xref>), and AXL (<xref ref-type="bibr" rid="bib28">Kim et al., 2019</xref>; <xref ref-type="bibr" rid="bib58">Taniguchi et al., 2019</xref>; <xref ref-type="bibr" rid="bib25">Jimbo et al., 2019</xref>; <xref ref-type="bibr" rid="bib39">Namba et al., 2019</xref>). The variety of RTK bypass pathways that can lead to osimertinib resistance suggests that broad inhibition of RTK signaling may be a more effective therapeutic strategy than any individual RTK inhibitor to limit osimertinib resistance, whereas once resistance via oncogenic shift to an alternative RTK occurs then inhibition of the upregulated RTK would have therapeutic benefit. Toward this end, Phase I and II clinical trials are currently examining whether combining osimertinib with inhibitors of AXL (DS-1205c, NCT03255083) or c-MET (teponitib, NCT03940703; savolitinib, NCT03778229) are effective in patients who have progressed on osimertinib treatment.</p><p>Combining osimertinib with a MEK inhibitor can enhance osimertinib efficacy (<xref ref-type="bibr" rid="bib8">Eberlein et al., 2015</xref>; <xref ref-type="bibr" rid="bib59">Tricker et al., 2015</xref>; <xref ref-type="bibr" rid="bib18">Ichihara et al., 2017</xref>; <xref ref-type="bibr" rid="bib53">Shi et al., 2017</xref>; <xref ref-type="bibr" rid="bib6">Della Corte et al., 2018</xref>) and Phase II clinical trials are currently underway to assess combining osimertinib with the MEK inhibitor selumetinib in EGFR-mutated NSCLC (NCT03392246), although resistance to combined osimertinib and MEK inhibition still occurs (<xref ref-type="bibr" rid="bib59">Tricker et al., 2015</xref>). In a recent study designed to understand resistance to combined osimertinib and MEK inhibition, <xref ref-type="bibr" rid="bib30">Kurppa et al., 2020</xref> show that combining osimertinib with the MEK inhibitor trametinib results in <italic>EGFR</italic>-mutated cells entering a senescent state that is dependent on the activation of the Hippo pathway effector YAP and its transcription-factor-binding partner TEAD (<xref ref-type="bibr" rid="bib30">Kurppa et al., 2020</xref>). Inhibition of YAP/TEAD signaling overcame this senescence and enhanced killing of EGFR-mutated cells (<xref ref-type="bibr" rid="bib30">Kurppa et al., 2020</xref>). EGFR-signaling drives YAP nuclear translocation and transcriptional regulation through PI3K-PDK1 signaling (<xref ref-type="bibr" rid="bib11">Fan et al., 2013</xref>; <xref ref-type="bibr" rid="bib63">Xia et al., 2018</xref>; <xref ref-type="bibr" rid="bib60">Tumaneng et al., 2012</xref>). This suggest that therapeutic combinations able to synergistically inhibit both Raf/MEK/ERK and PI3K/AKT effector signaling should overcome YAP-dependent senescence and treat <italic>EGFR</italic>-mutated NSCLC.</p><p>Here, we show that osimertinib does not broadly synergize with inhibitors of downstream EGFR/RAS/RAS effector signaling. Instead, we found that synergy was limited to combinations of osimertinib with inhibitors of proximal EGFR signaling intermediates SOS1 and SHP2 (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Further, SOS1 inhibition significantly enhanced osimertinib-dependent inhibition of both Raf/MEK/ERK and PI3K/AKT signaling (<xref ref-type="fig" rid="fig6">Figure 6</xref>), whereas inhibition of individual downstream Raf/MEK/ERK or PI3K/AKT effector pathways did not synergize with osimertinib (<xref ref-type="fig" rid="fig7">Figure 7</xref>) to inhibit 3D spheroid growth. We hypothesize that these two findings are inexorably linked, so that any potential therapeutic must synergize with osimertinib to inhibit all downstream RAS effector signaling to show drug-drug synergy in 3D culture. In support of this idea, previous studies showed inhibition of SRC family kinases (SFK) potentiated osimertinib to a much greater extent than either MEK or PI3K inhibition (<xref ref-type="bibr" rid="bib18">Ichihara et al., 2017</xref>), and that SFK inhibition synergized with osimertinib to inhibit both Raf/MEK/ERK and PI3K/AKT signaling (<xref ref-type="bibr" rid="bib18">Ichihara et al., 2017</xref>; <xref ref-type="bibr" rid="bib62">Watanabe et al., 2017</xref>).</p><p>There remain several open questions regarding SOS1 inhibition as a therapeutic strategy to limit osimertinib resistance. First, does SOS1 inhibition enhance osimertinib efficacy in vivo using xenograft studies? While BAY-293 shows tremendous specificity toward SOS1 (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 1 and 2</xref>, and <xref ref-type="bibr" rid="bib16">Hillig et al., 2019</xref>) and is a very useful tool compound for in vitro studies, it has limited bioavailability making it unsuitable for in vivo use. Thus, new SOS1 inhibitors that can be used in vivo are needed to move SOS1 forward as a therapeutic target. Intriguingly, while this paper was under review Boehringer Ingelheim reported two orally available SOS1 inhibitors suitable for in vivo studies (<xref ref-type="bibr" rid="bib17">Hofmann et al., 2020</xref>). They found that SOS1 inhibition could overcome MEK inhibitor resistance in <italic>KRAS</italic>-mutated cell lines and that the combination of SOS1 and MEK inhibition showed marked show efficacy in <italic>KRAS</italic>-mutated cell lines and xenograft models. They are now moving one of these compounds into Phase I safety trials for <italic>KRAS</italic> mutated solid tumors (BI-1701963, NCT04111458). It will be exciting to assess whether these new SOS1 inhibitors work in combination with osimertinib to limit the growth <italic>EGFR-</italic>mutated tumors. Further, these studies will be necessary to translate SOS1-targeted therapies for use in <italic>EGFR</italic>-mutated lung adenocarcinoma. Second, does SOS1 inhibition actually limit the development of osimertinib resistance? While outside the scope of the current paper, it will be intriguing to use in vitro models of EGFR-TKI resistance (<xref ref-type="bibr" rid="bib59">Tricker et al., 2015</xref>) to assess whether SOS1 inhibition can block the development of osimertinib resistance. Third, while we have focused on the RAF/MEK/ERK and PI3K/AKT effector pathways as the major contributors to mutant <italic>EGFR</italic>-driven NSCLC, there are many different effector pathways downstream of RAS that may be SOS1-dependent and contribute to the oncogenic phenotype. Here, and unbiased approach at understanding the individual and combined effects of osimertinib and SOS1 inhibition on RAS activation (to validate relatively new SOS1 inhibitors) and RAS effector signaling would provide valuable insight into how these therapies alter EGFR-driven signaling in NSCLC.</p><p>Overall, our data suggest that inhibitors of proximal signaling may be the most efficacious therapeutics to combine with osimertinib to treat EGFR-mutated tumors. Toward this end, Phase I trials are currently underway assessing the combination of osimertinib and the SRC inhibitor dasatinib (NCT02954523) in <italic>EGFR</italic>-mutated NSCLC, and recently developed SOS1 (BI-1701963, NCT04111458) and SHP2 (JAB-3068, NCT03565003; RMC-4630, NCT03634982) inhibitors have entered Phase I safety trials. Our study provides a framework for the systematic, preclinical assessment of therapeutic combinations designed to treat EGFR-mutated cancer cells. We show both how to use basic pharmacologic principles to assess drug-drug synergy and that these combinations must be assessed under 3D culture conditions. Using this framework, we show that the combination of osimertinib and the SOS1 inhibitor BAY-293 shows marked efficacy in 3D spheroid culture and should be pursued as a therapeutic option to treat EGFR-mutated lung adenocarcinoma.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type <break/>(species) or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Lung; adenocarcinoma; non-small cell lung cancer</td><td valign="top">Obtained from Udayan Guha, available at ATCC</td><td valign="top">NCI-H1975 <break/>CRL-5908 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_UE30">CVCL_UE30</ext-link></td><td valign="top"/></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Lung; adenocarcinoma; epithelial</td><td valign="top">Obtained from Udayan Guha, available at ATCC</td><td valign="top">HCC827 <break/>CRL-2868 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_DH92">CVCL_DH92</ext-link></td><td valign="top"/></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Lung; adenocarcinoma; non-small cell lung cancer</td><td valign="top">Obtained from Udayan Guha, available at NCI-DTP or ATCC</td><td valign="top">NCI-H3255 <break/>CRL-2882NCI-DTP Cat# NCI-H3255, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_6831">CVCL_6831</ext-link></td><td valign="top"/></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Lung; adenocarcinoma; non-small cell lung cancer</td><td valign="top"><xref ref-type="bibr" rid="bib5">de Bruin et al., 2014</xref></td><td valign="top">NCI-H3255TM</td><td valign="top"/></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Dermal fibroblast (normal, Adult)</td><td valign="top">Obtained from Udayan Guha, available at Millipore Sigma or BCRJ</td><td valign="top">PC9 <break/>#90071810 <break/>BCRJ Cat# 0331, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_B260">CVCL_B260</ext-link></td><td valign="top"/></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Lung; adenocarcinoma; non-small cell lung cancer</td><td valign="top"><xref ref-type="bibr" rid="bib10">Engelman et al., 2006</xref></td><td valign="top">PC9-TM</td><td valign="top"/></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">Kidney; epithelial fibroblast (fetus)</td><td valign="top">ATCC</td><td valign="top">HEK-293T <break/>ATCC Cat# CRL-3216, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/CVCL_0063">CVCL_0063</ext-link></td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">TransIT-Lenti</td><td valign="top">Mirus</td><td valign="top">Catalogue # MIR 6605</td><td valign="top">Lentiviral transduction reagent</td></tr><tr><td valign="top">Other</td><td valign="top">MISSION Lentiviral packaging mix</td><td valign="top">Millipore Sigma</td><td valign="top">Catalogue # SHP001</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">Bovine Serum Albumin</td><td valign="top">Millipore Sigma</td><td valign="top">Catalogue # A8022</td><td valign="top">Cell culture reagent for ACL-4 media</td></tr><tr><td valign="top">Other</td><td valign="top">apo-Transferrin (human)</td><td valign="top">Millipore Sigma</td><td valign="top">Catalogue # T5391</td><td valign="top">Cell culture reagent for ACL-4 media</td></tr><tr><td valign="top">Other</td><td valign="top">Sodium Selenite</td><td valign="top">Millipore Sigma</td><td valign="top">Catalogue # S9133</td><td valign="top">Cell culture reagent for ACL-4 media</td></tr><tr><td valign="top">Other</td><td valign="top">Hydrocortisone</td><td valign="top">Millipore Sigma</td><td valign="top">Catalogue # H0135</td><td valign="top">Cell culture reagent for ACL-4 media</td></tr><tr><td valign="top">Other</td><td valign="top">Ethanolamine</td><td valign="top">Millipore Sigma</td><td valign="top">Catalogue # E0135</td><td valign="top">Cell culture reagent for ACL-4 media</td></tr><tr><td valign="top">Other</td><td valign="top">O-Phosphorylethanolamine</td><td valign="top">Millipore Sigma</td><td valign="top">Catalogue # P0503</td><td valign="top">Cell culture reagent for ACL-4 media</td></tr><tr><td valign="top">Other</td><td valign="top">3,3’,5-Triiodo-L-thyronine [T3]</td><td valign="top">Millipore Sigma</td><td valign="top">Catalogue # T5516</td><td valign="top">Cell culture reagent for ACL-4 media</td></tr><tr><td valign="top">Other</td><td valign="top">Sodium Pyruvate</td><td valign="top">Millipore Sigma</td><td valign="top">Catalogue # P4562</td><td valign="top">Cell culture reagent for ACL-4 media</td></tr><tr><td valign="top">Other</td><td valign="top">HEPES</td><td valign="top">Invitrogen</td><td valign="top">Catalogue # 15630–080</td><td valign="top">Cell culture reagent for ACL-4 media</td></tr><tr><td valign="top">Other</td><td valign="top">Epidermal Growth Factor [EGF]</td><td valign="top">Millipore Sigma</td><td valign="top">Catalogue # E4127</td><td valign="top">Cell culture reagent for ACL-4 media</td></tr><tr><td valign="top">Other</td><td valign="top">Recombinant Human Insulin</td><td valign="top">Millipore Sigma</td><td valign="top">Catalogue # I9278</td><td valign="top">Cell culture reagent for ACL-4 media</td></tr><tr><td valign="top">Other</td><td valign="top">AggreWell 400 low-attachment culture plates</td><td valign="top">Stem Cell</td><td valign="top">Catalogue # 34415</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">ultra-low attachment 96-well round bottomed plates</td><td valign="top">Corning Corstar</td><td valign="top">Catalogue # 7007</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">Nunc Nucleon Sphera microplates</td><td valign="top">ThermoFisher</td><td valign="top">Catalogue # 174929</td><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">coated 96-well white-walled CulturePlates</td><td valign="top">Perken Elmer</td><td valign="top">Catalogue # 6005688</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">anti-Sos 1 Antibody (C-23): sc-256, rabbit polyclonal</td><td valign="top">Santa Cruz</td><td valign="top">sc-256</td><td valign="top">(1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-SOS2 antibody (C-19): sc-258, rabbit polyclonal</td><td valign="top">Santa Cruz</td><td valign="top">sc-258</td><td valign="top">(1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-β-actin antibody AC15, mouse monoclonal</td><td valign="top">Millipore Sigma</td><td valign="top">#A1978</td><td valign="top">(1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-Phospho-EGF Receptor (Tyr1068) (D7A5) XP Rabbit mAb #3777</td><td valign="top">Cell Signaling Technology</td><td valign="top">#3777</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-phospho p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XPRabbit mAb #4370</td><td valign="top">Cell Signaling Technology</td><td valign="top">#4370</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-p44/42 MAPK (Erk1/2) (L34F12) Mouse mAb #4696</td><td valign="top">Cell Signaling Technology</td><td valign="top">#4696</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti- Phospho-Akt (Ser473) (D9E) XPRabbit mAb #4060</td><td valign="top">Cell Signaling Technology</td><td valign="top">#4060</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti- Akt (pan) (40D4) Mouse mAb #2920</td><td valign="top">Cell Signaling Technology</td><td valign="top">#2920</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-HSP 90α/β Antibody (H-114): sc-7947</td><td valign="top">Santa Cruz</td><td valign="top">#sc-7947</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">anti-EGF Receptor (D38B1) XPRabbit mAb #4267</td><td valign="top">Cell Signaling Technology</td><td valign="top">#4267</td><td valign="top">(1:1000)</td></tr><tr><td valign="top">Recombinant DNA Reagent</td><td valign="top">pLentiCrispr v2</td><td valign="top"><xref ref-type="bibr" rid="bib48">Sanjana et al., 2014</xref></td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Other</td><td valign="top">CellTiter-Glo 2.0</td><td valign="top">Promega</td><td valign="top">G9243</td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pLentiCrispr. <break/>NT</td><td valign="top"><xref ref-type="bibr" rid="bib50">Sheffels et al., 2018</xref></td><td valign="top">NT</td><td valign="top">sgRNA: <named-content content-type="sequence">CCATATCGGGGCGAGACATG</named-content></td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pLentiCrispr. SOS2-9</td><td valign="top"><xref ref-type="bibr" rid="bib50">Sheffels et al., 2018</xref></td><td valign="top">SOS2-9</td><td valign="top">sgRNA: <named-content content-type="sequence">GAGAACAGTCCGAAATGGCG</named-content></td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pLentiCrispr. SOS1-1</td><td valign="top">This manuscript</td><td valign="top">SOS1-1</td><td valign="bottom">sgRNA: <named-content content-type="sequence">GGGCAGCTGCTGCGCCTGCA</named-content></td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pLentiCrispr. SOS1-2</td><td valign="top">This manuscript</td><td valign="top">SOS1-2</td><td valign="bottom">sgRNA: <named-content content-type="sequence">GCATCCTTTCCAGTGTACTC</named-content></td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pLentiCrispr. SOS1-3</td><td valign="top">This manuscript</td><td valign="top">SOS1-3</td><td valign="bottom">sgRNA: <named-content content-type="sequence">TATTCTGCATTGCTAGCACC</named-content></td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pLentiCrispr. SOS1-4</td><td valign="top">This manuscript</td><td valign="top">SOS1-4</td><td valign="bottom">sgRNA: <named-content content-type="sequence">AGTGGCATATAAGCAGACCT</named-content></td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pLentiCrispr. SOS1-5</td><td valign="top">This manuscript</td><td valign="top">SOS1-5</td><td valign="bottom">sgRNA: <named-content content-type="sequence">ATTGCAAGAGACAATGGACC</named-content></td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pLentiCrispr. SOS1-6</td><td valign="top">This manuscript</td><td valign="top">SOS1-6</td><td valign="bottom">sgRNA: <named-content content-type="sequence">GCTTATATGCCACTCAACTG</named-content></td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pLentiCrispr. SOS1-7</td><td valign="top">This manuscript</td><td valign="top">SOS1-7</td><td valign="bottom">sgRNA: <named-content content-type="sequence">GAAGGAACTCTTACACGTGT</named-content></td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pLentiCrispr. SOS1-8</td><td valign="top">This manuscript</td><td valign="top">SOS1-8</td><td valign="bottom">sgRNA: <named-content content-type="sequence">CTATTGGGTGTAAGGTGAGC</named-content></td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell culture</title><p>Cell lines were cultured at 37°C and 5% CO<sub>2</sub>. HCC827, NCI-H1975, PC9, and PC9-TM cells were maintained in Roswell Park Memorial Institute medium (RPMI), each supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. Cell lines were authenticated by STR profiling and confirmed as mycoplasma negative. EGFR mutations were confirmed by Sanger sequencing. H3255 and H3255-TM were maintained in ACL4 medium formulated in DMEM:F-12 including: Bovine Serum Albumin 0.5% (w/v) (Sigma cat no. A8022), apo-Transferrin (human) (Sigma cat no. T5391) 0.01 mg/mL, Sodium Selenite (Sigma cat no. S9133) 25 nM, Hydrocortisone (Sigma cat no. H0135) 50 nM, Ethanolamine (Sigma cat no. E0135) 0.01 mM, O-Phosphorylethanolamine (Sigma cat no. P0503) 0.01 mM, 3,3’,5-Triiodo-L-thyronine [T3] (Sigma cat no. T5516) 100pM, Sodium Pyruvate (Sigma cat no. P4562), HEPES (Invitrogen cat no 15630–080) 10 mM, Epidermal Growth Factor [EGF] 1 ng/mL, Recombinant Human Insulin (Sigma cat no. I9278) 0.02 mg/mL, and 1% penicillin-streptomycin. For signaling experiments, cells were seeded in 24-well micropatterned AggreWell 400 low-attachment culture plates (Stem Cell # 34415) at 1.2 × 10<sup>6</sup> cells/well in 2 mL of medium. 24 hr post-plating, half of the media was carefully replaced with fresh media to not disturb the spheroids. At 48 hr, 1 mL media was removed and replaced with 2 x inhibitor. Cells were treated with inhibitor for 6 hr and then collected for cell lysis and western blot analysis.</p></sec><sec id="s4-2"><title>Cell lysis and western blot analysis</title><p>Cells were lysed in RIPA buffer (1% NP-40, 0.1% SDS, 0.1% Na-deoxycholate, 10% glycerol, 0.137 M NaCl, 20 mM Tris pH [8.0], protease (Biotool #B14002) and phosphatase (Biotool #B15002) inhibitor cocktails) for 20 min at 4°C and spun at 10,000 RPM for 10 min. Clarified lysates were boiled in SDS sample buffer containing 100 mM DTT for 10 min prior to western blotting. Proteins were resolved by sodium dodecyl sulfate-polyacrylamide (Criterion TGX precast) gel electrophoresis and transferred to nitrocellulose membranes. Western blots were developed by multiplex Western blotting using anti-SOS1 (Santa Cruz sc-256; 1:500), anti-SOS2 (Santa Cruz sc-258; 1:500), anti-β-actin (Sigma AC-15; 1:5,000), anti-pEGFR (Cell Signaling 3777; 1:1000), anti-EGFR (Cell Signaling 4267; 1:1000), anti-pERK1/2 (Cell Signaling 4370; 1:1,000), anti-ERK1/2 (Cell Signaling 4696; 1:1000), anti-pAKT Ser<sup>473</sup> (Cell Signaling 4060; 1:1000), anti-AKT (Cell Signaling 2920; 1:1000), anti-HSP90 (Santa Crux sc-7947, 1:1000), primary antibodies. Anti-mouse and anti-rabbit secondary antibodies conjugated to IRDye680 or IRDye800 (LI-COR; 1:10,000) were used to probe primary antibodies. Western blot protein bands were detected and quantified using the Odyssey system (LI-COR). For quantification of SOS1 and SOS2 abundance, samples were normalized to either β-actin or HSP90. For quantification of pERK and pAKT, samples were normalized to a weighted average of HSP90, β-actin, total ERK1/2, total AKT, and total EGFR (<xref ref-type="bibr" rid="bib21">Janes, 2015</xref>).</p></sec><sec id="s4-3"><title>Proliferation studies</title><p>For 2D proliferation assays, 5 × 10<sup>2</sup> cells were seeded on cell culture-coated 96-well white-walled CulturePlates (Perkin Elmer #6005688). Cells were lysed with CellTiter-Glo 2.0 Reagent (Promega), and luminescence was read using a Bio-Tek Cytation five multi-mode plate reader. Cell number was assessed 24 hr after plating to account for any discrepancies in plating (Day 1), and then on days 3, 5, and 7. Data were analyzed as an increase in luminescence over Day 1.</p></sec><sec id="s4-4"><title>Transformation studies</title><p>H3255 and H3255-TM cells were seeded in 0.32% Nobel agar at 2 × 10<sup>4</sup> cells per 35 mm dish to assess anchorage-independent. Soft agar colonies were counted 28 days after seeding. For all other cell lines spheroid growth assessed in ultra-low attachment 96-well round bottomed plates (Corning Costar #7007), cells were seeded at 500 cells per well. Images were taken 24 hr after plating to assess initial spheroid size, and then 7, 14, and 21 days later to assess transformation. Cell number was assessed in parallel plates at 0, 7, 14, and 21 days using CellTiter-Glo 2.0 reagent.</p></sec><sec id="s4-5"><title>sgRNA studies</title><p>A non-targeting (NT) single guide RNA (sgRNA), a SOS2-targeted sgRNA (<xref ref-type="bibr" rid="bib50">Sheffels et al., 2018</xref>), and eight potential SOS1-targeted sgRNAs previously used to target SOS1 in a genome-wide CRISPR screen (<xref ref-type="bibr" rid="bib38">Munoz et al., 2016</xref>) were each cloned into pLentiCRISPRv2 as previously described (<xref ref-type="bibr" rid="bib48">Sanjana et al., 2014</xref>). SOS1-2 was chosen as the SOS1 sgRNA for the study, and SOS2-9 was chosen as previously described (<xref ref-type="bibr" rid="bib50">Sheffels et al., 2018</xref>). For studies in <xref ref-type="fig" rid="fig1">Figure 1</xref>, cells were infected lentivirus to express the given sgRNA with Cas9, and cells were selected for 10 days with puromycin prior to Western blotting. Cell lysates were probed for SOS1 or SOS2, and only cell populations showing grater that 80% SOS deletion within the overall population were used. Importantly, cell clones were not used, rather cell populations where &gt; 80% of cells showed SOS deletion were used to minimize clonal effects. Independent infections were used for each experiment.</p><p><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Construct</th><th valign="top">sgRNA</th></tr></thead><tbody><tr><td valign="top">NT</td><td valign="top"><named-content content-type="sequence">CCATATCGGGGCGAGACATG</named-content></td></tr><tr><td valign="top">SOS2-9</td><td valign="top"><named-content content-type="sequence">GAGAACAGTCCGAAATGGCG</named-content></td></tr><tr><td valign="top">SOS1-1</td><td valign="bottom"><named-content content-type="sequence">GGGCAGCTGCTGCGCCTGCA</named-content></td></tr><tr><td valign="top">SOS1-2</td><td valign="bottom"><named-content content-type="sequence">GCATCCTTTCCAGTGTACTC</named-content></td></tr><tr><td valign="top">SOS1-3</td><td valign="bottom"><named-content content-type="sequence">TATTCTGCATTGCTAGCACC</named-content></td></tr><tr><td valign="top">SOS1-4</td><td valign="bottom"><named-content content-type="sequence">AGTGGCATATAAGCAGACCT</named-content></td></tr><tr><td valign="top">SOS1-5</td><td valign="bottom"><named-content content-type="sequence">ATTGCAAGAGACAATGGACC</named-content></td></tr><tr><td valign="top">SOS1-6</td><td valign="bottom"><named-content content-type="sequence">GCTTATATGCCACTCAACTG</named-content></td></tr><tr><td valign="top">SOS1-7</td><td valign="bottom"><named-content content-type="sequence">GAAGGAACTCTTACACGTGT</named-content></td></tr><tr><td valign="top">SOS1-8</td><td valign="bottom"><named-content content-type="sequence">CTATTGGGTGTAAGGTGAGC</named-content></td></tr></tbody></table></table-wrap></p></sec><sec id="s4-6"><title>Production of recombinant lentiviruses</title><p>Lentiviruses were produced by co-transfecting MISSION lentiviral packaging mix (Sigma) into 293 T cells using Mirus <italic>Trans</italic>IT-Lenti transfection reagent (Mirus Bio # MIR6605) in Opti-MEM (Thermo Scientific #31-985-062). At 48 hr post-transfection, viral supernatants were collected and filtered. Viral supernatants were then either stored at −80°C or used immediately to infect cells in combination with polybrene at 8 μg/mL. 48 hr post-infection, cells were selected in 4 μg/mL Puromycin (Invitrogen). Twelve days after selection, cells were analyzed for SOS1 and SOS2 expression and plated for proliferation and transformation assays.</p></sec><sec id="s4-7"><title>Inhibitor studies</title><list list-type="bullet"><list-item><p>2D adherent studies – Cells were seeded at 500–1,000 cells per well in 100 μL in the inner-60 wells of 96-well white-walled culture plates (Perkin Elmer) and allowed to attach for 48 hr prior to drug treatment. Cells were treated with drug for 72 hr prior to assessment of cell viability using CellTiter-Glo 2.0.</p></list-item><list-item><p>3D adherent studies – Cells were seeded at 500–1,000 cells per well in 100 μL in the inner-60 wells of 96-well ultra-low attachment round bottomed plates (Corning #7007) or Nunc Nucleon Sphera microplates (ThermoFisher # 174929) and allowed to coalesce as spheroids for 48–72 hr prior to drug treatment. Cells were treated with drug for 96 hr prior to assessment of cell viability using CellTiter-Glo 2.0.</p></list-item></list><p>For all studies, outer wells (rows A and H, columns 1 and 12) were filled with 200 μL of PBS to buffer inner cells from temperature and humidity fluctuations. Triplicate wells of cells were then treated with increasing concentrations 100 μL of 2 × inhibitor at either a semilog (single drug dose response curves to determine EC<sub>50</sub>) or a 1/3-log scale (isobologram and Bliss independence experiments) for 72 (adherent cultures) or 96 (spheroids) hr. Cell viability was assessed using CellTiter-Glo 2.0 (30 μL/well). Luminescence was assessed using a Bio-Tek Cytation five multi-mode plate reader. Data were normalized to the maximum luminescence reading of untreated cells, and individual drug EC<sub>50</sub> values were calculated using Prism eight by non-linear regression using log(inhibitor) vs. response with a variable slope (four parameters) to assess for differences in the Hill Coefficient between different drug treatments. For all drug-treatment studies, the untreated sample for each cell line was set to 100%. This would mask any differences in 3D cell proliferation seen between cell lines.</p></sec><sec id="s4-8"><title>Isobologram analysis</title><p>Dose equivalence was first determined by assessing individual-drug EC<sub>50</sub> values; individual-drug Hill Coefficients were determined to assure that the two drugs could be assessed for synergy by Lowe additivity. To generate dose-equivalent dose-response curves, the dose for each drug closest to the EC<sub>50</sub> on a 1/3-log scale was set as equivalent, and 10-point dose response curves were generated for each individual drug on either side of the equivalent dose to ensure the top (no drug effect) and bottom (maximal drug effect) were represented on the dose-response curve. 100 μL of drug each drug dose was added as outlined above. To generate dose-equivalent mixtures for isobologram analysis, equivalent doses of the two drugs were mixed at different ratios so that the total dose (100 μL) would be expected to have an equivalent effect on the cells if the two drugs were additive. Drugs were mixed at either five (4:1, 2:1, 1:1, 1:2, and 1:4) or three (2:1, 1:1, and 1:2) different drug mixtures depending on the experiment. Cells were treated and EC<sub>50</sub> values for each individual drug or drug mixture based on each drug’s dosing were determined for as outlined above. To generate an isobologram plot, the EC<sub>50</sub> of each individual drug was plotted as the x- or y-intercept, and the calculated contribution of each drug to the overall EC<sub>50</sub> for each DEQ mix is plotted as a single point (EC<sub>50,A</sub>, EC<sub>50,B</sub>) on the graph.<disp-formula id="equ1"><mml:math id="m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi mathvariant="normal">A</mml:mi><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi mathvariant="normal">A</mml:mi><mml:mrow><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi mathvariant="normal">B</mml:mi><mml:mrow><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:msub><mml:mi mathvariant="normal">B</mml:mi><mml:mrow><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>To calculate the combination index for each dose equivalent mixture, the calculated contribution of each drug to the overall EC<sub>50</sub> were used in the equation:</p><p>As an example, we will show data for one trial analyzing the combination of osimertinib and BAY-293 in 3D spheroid cultured H1975 cells in <xref ref-type="fig" rid="fig2">Figure 2B</xref>. The EC<sub>50</sub> values for each individual drug were first determined: −8.57 for osimertinib and −5.73 for BAY-293. Based on these EC<sub>50</sub> values, the dose equivalence was set at −8.67 for osimertinib −5.67 for BAY-293 (approximated EC<sub>50</sub> for each drug in bold), and the following 10-point dose response curves were generated:</p><p><table-wrap id="inlinetable2" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Osimertinib</th><th>−11</th><th>−10.67</th><th>−10.33</th><th>−10</th><th>−9.67</th><th>−9.33</th><th>-9</th><th>−8.67</th><th>−8.33</th><th>-8</th></tr></thead><tbody><tr><td>BAY-293</td><td>-8</td><td>−7.67</td><td>−7.33</td><td>-7</td><td>−6.67</td><td>−6.33</td><td>-6</td><td><bold>−5.67</bold></td><td>−5.33</td><td>-5</td></tr></tbody></table></table-wrap></p><p>Cells were then treated with the following volumes of each drug to generate seven dose-equivalent dose response curves:</p><p><table-wrap id="inlinetable3" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th valign="top"/><th>4:1 mixture</th><th>2:1 mixture</th><th>1:1 mixture</th><th>1:2 <break/>mixture</th><th>1:4 mixture</th><th valign="top"/></tr></thead><tbody><tr><td valign="top">osimertinib</td><td>100 μL</td><td>80 μL</td><td>66 μL</td><td>50 μL</td><td>34 μL</td><td>20 μL</td><td>0 μL</td></tr><tr><td valign="top">BAY-293</td><td>0 μL</td><td>20 μL</td><td>34 μL</td><td>50 μL</td><td>66 μL</td><td>80 μL</td><td>100 μL</td></tr></tbody></table></table-wrap></p><p>EC<sub>50</sub> values for each dose-response curve were then determined based on each drug’s dosing:</p><p><table-wrap id="inlinetable4" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th>OSM alone</th><th>4:1 mixture</th><th>2:1 mixture</th><th>1:1 mixture</th><th>1:2 <break/>mixture</th><th>1:4 mixture</th><th>BAY alone</th></tr></thead><tbody><tr><td valign="top">osimertinib <break/>EC<sub>50</sub> (nM)</td><td valign="bottom">2.62</td><td valign="bottom">0.84</td><td valign="bottom">0.70</td><td valign="bottom">0.92</td><td valign="bottom">1.49</td><td valign="bottom">1.19</td><td valign="bottom">2.40</td></tr><tr><td valign="top">BAY-293 <break/>EC<sub>50</sub> (μM)</td><td valign="bottom">2.14</td><td valign="bottom">1.01</td><td valign="bottom">0.83</td><td valign="bottom">1.09</td><td valign="bottom">1.49</td><td valign="bottom">1.04</td><td valign="bottom">1.82</td></tr></tbody></table></table-wrap></p><p>EC<sub>50</sub> values were then adjusted based on the amount of each drug that was put in the mixture to determine the contribution of each drug in the mixture to the overall EC<sub>50</sub>. For example, the 4:1 mixture was 80% osimertinib, so the osimertinib EC50 for that mixture is multiplied by 0.8. The corresponding corrected EC<sub>50</sub> values and combination indices were:</p><p><table-wrap id="inlinetable5" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th>OSM alone</th><th>4:1 mixture</th><th>2:1 mixture</th><th>1:1 mixture</th><th>1:2 <break/>mixture</th><th>1:4 mixture</th><th>BAY alone</th></tr></thead><tbody><tr><td valign="top">osimertinib <break/>EC<sub>50</sub> (nM)</td><td valign="bottom">2.62</td><td valign="bottom">0.67</td><td valign="bottom">0.45</td><td valign="bottom">0.46</td><td valign="bottom">0.52</td><td valign="bottom">0.24</td><td valign="bottom">0</td></tr><tr><td valign="top">BAY-293 <break/>EC<sub>50</sub> (μM)</td><td valign="bottom">0</td><td valign="bottom">0.20</td><td valign="bottom">0.29</td><td valign="bottom">0.54</td><td valign="bottom">0.97</td><td valign="bottom">0.84</td><td valign="bottom">1.82</td></tr><tr><td valign="top">Combination <break/>Index</td><td valign="bottom"/><td valign="bottom">0.40</td><td valign="bottom">0.34</td><td valign="bottom">0.44</td><td valign="bottom">0.65</td><td valign="bottom">0.46</td><td valign="bottom"/></tr></tbody></table></table-wrap></p></sec><sec id="s4-9"><title>Bliss independence analysis</title><p>Unlike Isobologram analysis, individual drug doses are not reduced for drug-drug combinations when performing Bliss independence analysis. For data in <xref ref-type="fig" rid="fig2">Figure 2</xref>, wells were treated with a full dose of each individual drug or drug combination in a 10 × 10 matrix of dose combinations for osimertinib and BAY-293 on a 1/3-log scale. Data were normalized to the maximum luminescence reading of untreated cells, and a heat-map depicting cell viability was generated using Prism 8. The Bliss index was calculated by first converting viability (on a scale of 0 to 1) for each treatment to the effect of each drug or drug combination, where 0 represents no effect and 1 represents 100% effect (no viable cells).<disp-formula id="equ2"><mml:math id="m2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">y</mml:mi></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>From the effect data, the expected effect for each drug combination is calculated:<disp-formula id="equ3"><mml:math id="m3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">A</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">B</mml:mi></mml:msub><mml:mo>∗</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">A</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ4"><mml:math id="m4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">A</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">B</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi mathvariant="normal">E</mml:mi><mml:mrow><mml:mi mathvariant="normal">A</mml:mi></mml:mrow></mml:msub><mml:mo>∗</mml:mo><mml:msub><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">B</mml:mi></mml:msub></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>The <underline>Bliss Index</underline> is the ratio of the expected effect/actual effect:<disp-formula id="equ5"><mml:math id="m5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mspace width="thinmathspace"/><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mspace width="thinmathspace"/><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ6"><mml:math id="m6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">A</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">B</mml:mi></mml:msub><mml:mo>–</mml:mo><mml:msub><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">A</mml:mi></mml:msub><mml:mo>∗</mml:mo><mml:msub><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">B</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mspace width="thinmathspace"/><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mspace width="thinmathspace"/><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="normal">E</mml:mi><mml:mrow><mml:mi mathvariant="normal">A</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">B</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">X</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>A Bliss Index of 1 indicates that the actual and expected effects are equivalent, and the effects of the two drugs are additive. Bliss Index &lt; 1 indicates increasing synergy, whereas Bliss Index &gt; 1 indicates antagonism.</p><p><underline>Excess over Bliss</underline> is calculated by determining how much greater the actual effect of the drug combination is versus the expected effect, and is calculated as:<disp-formula id="equ7"><mml:math id="m7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mn>100</mml:mn><mml:mo>∗</mml:mo></mml:msup><mml:mo stretchy="false">[</mml:mo><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mo>–</mml:mo><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ8"><mml:math id="m8"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mn>100</mml:mn><mml:mo>∗</mml:mo></mml:msup><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi mathvariant="normal">E</mml:mi><mml:mrow><mml:mi mathvariant="normal">A</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">X</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">A</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">B</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">A</mml:mi></mml:msub><mml:mo>∗</mml:mo><mml:msub><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">B</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mstyle></mml:math></disp-formula></p><p>An excess over Bliss of 0 indicates that the actual and expected effects are equivalent, and the effects of the two drugs are additive; values &gt; 0 indicate increasing synergy, whereas values &lt; 0 indicate antagonism.</p><p>Since synergy occurred at drug combinations at or just below the EC<sub>50</sub> values for each individual drug, Bliss experiments in <xref ref-type="fig" rid="fig4">Figures 4</xref> and <xref ref-type="fig" rid="fig5">5</xref>, drug mixtures were limited to 3 × 10 drug mixtures based on dose equivalence with mixtures at approximately 2:1, 1:1, and 1:2 mixes of the two drugs based on dose equivalence. Here, the doses used for one drug were held constant, and the second drug dose wash shifted by 1/3 log up or down to generate 2:1 and 1:2 mixtures. For example, for the combination of osimertinib and BAY-293 in H1975 cells, the following drug doses were used:</p><p><table-wrap id="inlinetable6" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Osimertinib <break/>(1:2 ratio of <break/>OSM:BAY)</th><th>−11.33</th><th>−11</th><th>−10.67</th><th>−10.33</th><th>−10</th><th>−9.67</th><th>−9.33</th><th>-9</th><th>−8.67</th><th>−8.33</th></tr></thead><tbody><tr><td>Osimertinib <break/>(1:1 ratio of <break/>OSM:BAY)</td><td>−11</td><td>−10.67</td><td>−10.33</td><td>−10</td><td>−9.67</td><td>−9.33</td><td>-9</td><td>−8.67</td><td>−8.33</td><td>-8</td></tr><tr><td>Osimertinib <break/>(2:1 ratio of <break/>OSM:BAY)</td><td>−10.67</td><td>−10.33</td><td>−10</td><td>−9.67</td><td>−9.33</td><td>-9</td><td>−8.67</td><td>−8.33</td><td>-8</td><td>−7.67</td></tr><tr><td>BAY-293 <break/>(constant)</td><td>-8</td><td>−7.67</td><td>−7.33</td><td>-7</td><td>−6.67</td><td>−6.33</td><td>-6</td><td>−5.67</td><td>−5.33</td><td>-5</td></tr></tbody></table></table-wrap></p></sec><sec id="s4-10"><title>Three-drug isobologram analysis</title><p>For three-drug isobologram studies with osimertinib (EC<sub>50</sub> = −8.57), BAY-293 (EC<sub>50</sub> = −5.74), and RCM-4550 (EC<sub>50</sub> = −6.84), drugs were again mixed based on dose equivalency. The dose-equivalent 10-point dose-response curves for these drugs in 3D cultured H1975 cells were (approximated EC<sub>50</sub> for each drug in bold):</p><p><table-wrap id="inlinetable7" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Osimertinib</th><th>−11</th><th>−10.67</th><th>−10.33</th><th>−10</th><th>−9.67</th><th>−9.33</th><th>-9</th><th>−8.67</th><th>−8.33</th><th>-8</th></tr></thead><tbody><tr><td>BAY-293</td><td>-8</td><td>−7.67</td><td>−7.33</td><td>-7</td><td>−6.67</td><td>−6.33</td><td>-6</td><td><bold>−5.67</bold></td><td>−5.33</td><td>-5</td></tr><tr><td>RMC-4550</td><td>-9</td><td><bold>−8.67</bold></td><td>−8.33</td><td>-8</td><td>−7.67</td><td>−7.33</td><td>-7</td><td><bold>−6.67</bold></td><td>−6.33</td><td>-6</td></tr></tbody></table></table-wrap></p><p>Each two-drug combination was set as a single ‘drug mixture’ at a 1:1 ratio, and the third drug was combined with this drug mixture at 2:1, 1:1, and 1:2 drug ratios. To generate the proper two and three-drug mixtures for analysis, 21 total dose response curves were generated. The five dose-response curves on the right represent the mixtures used to generate the isobologram plots in <xref ref-type="fig" rid="fig7">Figure 7D</xref>. The other two two-drug mixtures in <bold>bold</bold> (two-drug 2:1 and 1:2 mixtures) were used to generate the isobologram plots in <xref ref-type="fig" rid="fig7">Figure 7CCombination</xref> indices were calculated based on whether addition of the third drug to each two-drug 1:1 mixture further enhanced synergy when added to the two-drug mixture.</p><p>[osimertinib:BAY-293] mixture vs. RCM-4550:</p><p><disp-formula id="equ9"><mml:math id="m9"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">M</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:msub><mml:mi mathvariant="normal">Y</mml:mi><mml:mrow><mml:mn>3</mml:mn><mml:mo>−</mml:mo><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">M</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:msub><mml:mi mathvariant="normal">Y</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>:</mml:mo><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mn>3</mml:mn><mml:mo>−</mml:mo><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula><table-wrap id="inlinetable8" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th valign="top">OSM:BAY <break/>2:1</th><th valign="top">OSM:BAY <break/>1:2</th><th valign="top">Osm:BAY <break/>1:1</th><th>(1+1):1 <break/>2:1 mixture</th><th>(1+1):2 <break/>1:1 mixture</th><th>(1+1):4 <break/>1:2 <break/>mixture</th><th valign="top">RCM alone</th></tr></thead><tbody><tr><td valign="top">osimertinib</td><td><bold>66</bold> μ<bold>L</bold></td><td><bold>34</bold> μ<bold>L</bold></td><td>50 μL</td><td>33 μL</td><td>25 μL</td><td>17 μL</td><td>0 μL</td></tr><tr><td valign="top">BAY-293</td><td><bold>34</bold> μ<bold>L</bold></td><td><bold>66</bold> μ<bold>L</bold></td><td>50 μL</td><td>33 μL</td><td>25 μL</td><td>17 μL</td><td>0 μL</td></tr><tr><td valign="top">RMC-4550</td><td><bold>0</bold> μ<bold>L</bold></td><td><bold>0</bold> μ<bold>L</bold></td><td>0 μL</td><td>34 μL</td><td>50 μL</td><td>66 μL</td><td>100 μL</td></tr></tbody></table></table-wrap></p><p>[osimertinib:RCM-4550] mixture vs. BAY-293:</p><p><disp-formula id="equ10"><mml:math id="m10"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">M</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mn>3</mml:mn><mml:mo>−</mml:mo><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">M</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>:</mml:mo><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:msub><mml:mi mathvariant="normal">Y</mml:mi><mml:mrow><mml:mn>3</mml:mn><mml:mo>−</mml:mo><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:msub><mml:mi mathvariant="normal">Y</mml:mi><mml:mrow><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula><table-wrap id="inlinetable9" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th valign="top">OSM:RCM <break/>2:1</th><th valign="top">OSM:RCM <break/>1:2</th><th valign="top">Osm:RCM <break/>1:1</th><th>(1+1):1 <break/>2:1 mixture</th><th>(1+1):2 <break/>1:1 mixture</th><th>(1+1):4 <break/>1:2 <break/>mixture</th><th valign="top">RCM alone</th></tr></thead><tbody><tr><td valign="top">osimertinib</td><td><bold>66</bold> μ<bold>L</bold></td><td><bold>34</bold> μ<bold>L</bold></td><td>50 μL</td><td>33 μL</td><td>25 μL</td><td>17 μL</td><td>0 μL</td></tr><tr><td valign="top">BAY-293</td><td><bold>0</bold> μ<bold>L</bold></td><td><bold>0</bold> μ<bold>L</bold></td><td>0 μL</td><td>34 μL</td><td>50 μL</td><td>66 μL</td><td>100 μL</td></tr><tr><td valign="top">RMC-4550</td><td><bold>34</bold> μ<bold>L</bold></td><td><bold>66</bold> μ<bold>L</bold></td><td>50 μL</td><td>33 μL</td><td>25 μL</td><td>17 μL</td><td>0 μL</td></tr></tbody></table></table-wrap></p><p>[BAY-293:RCM-4550] mixture vs. osimertinib:</p><p><disp-formula id="equ11"><mml:math id="m11"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">Y</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mn>3</mml:mn><mml:mo>−</mml:mo><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">Y</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>:</mml:mo><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mn>3</mml:mn><mml:mo>−</mml:mo><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula><table-wrap id="inlinetable10" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th valign="top">BAY:RCM <break/>2:1</th><th valign="top">BAY:RCM <break/>1:2</th><th valign="top">Bay:RCM <break/>1:1</th><th>(1+1):1 <break/>2:1 mixture</th><th>(1+1):2 <break/>1:1 mixture</th><th>(1+1):4 <break/>1:2 <break/>mixture</th><th valign="top">RCM alone</th></tr></thead><tbody><tr><td valign="top">osimertinib</td><td><bold>0</bold> μ<bold>L</bold></td><td><bold>0</bold> μ<bold>L</bold></td><td>0 μL</td><td>34 μL</td><td>50 μL</td><td>66 μL</td><td>100 μL</td></tr><tr><td valign="top">BAY-293</td><td><bold>66</bold> μ<bold>L</bold></td><td><bold>34</bold> μ<bold>L</bold></td><td>50 μL</td><td>33 μL</td><td>25 μL</td><td>17 μL</td><td>0 μL</td></tr><tr><td valign="top">RMC-4550</td><td><bold>34</bold> μ<bold>L</bold></td><td><bold>66</bold> μ<bold>L</bold></td><td>50 μL</td><td>33 μL</td><td>25 μL</td><td>17 μL</td><td>0 μL</td></tr></tbody></table></table-wrap></p><p>To calculate the three-drug combination index where each drug was considered independently (<xref ref-type="fig" rid="fig7">Figure 7E</xref>), the following equation was used:<disp-formula id="equ12"><mml:math id="m12"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">x</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mn>3</mml:mn><mml:mo>−</mml:mo><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">O</mml:mi><mml:mi mathvariant="normal">S</mml:mi><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>:</mml:mo><mml:mn>50</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:msub><mml:mi mathvariant="normal">Y</mml:mi><mml:mrow><mml:mn>3</mml:mn><mml:mo>−</mml:mo><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mi mathvariant="normal">B</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:msub><mml:mi mathvariant="normal">Y</mml:mi><mml:mrow><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mn>3</mml:mn><mml:mo>−</mml:mo><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">x</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:msub><mml:mi mathvariant="normal">M</mml:mi><mml:mrow><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula></p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Udayan Guha for NCI-H1975, HCC827, PC9, H3255 and H3255-TM cells and for helpful discussions throughout the project. We thank Julian Downward for PC9-TM cells. Funding: This work was supported by grants from the Congressionally Directed Medical Research Program to RLK (LC160222 and LC180213).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Investigation, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Supplemental raw data.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-58204-data1-v1.xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-58204-transrepform-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 1, 2, 3, 4, 5, 6, 7, and Figure 1—figure supplement 2 and Figure 3—figure supplement 1.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balbin</surname> <given-names>OA</given-names></name><name><surname>Prensner</surname> <given-names>JR</given-names></name><name><surname>Sahu</surname> <given-names>A</given-names></name><name><surname>Yocum</surname> <given-names>A</given-names></name><name><surname>Shankar</surname> <given-names>S</given-names></name><name><surname>Malik</surname> <given-names>R</given-names></name><name><surname>Fermin</surname> <given-names>D</given-names></name><name><surname>Dhanasekaran</surname> <given-names>SM</given-names></name><name><surname>Chandler</surname> <given-names>B</given-names></name><name><surname>Thomas</surname> <given-names>D</given-names></name><name><surname>Beer</surname> <given-names>DG</given-names></name><name><surname>Cao</surname> <given-names>X</given-names></name><name><surname>Nesvizhskii</surname> <given-names>AI</given-names></name><name><surname>Chinnaiyan</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Reconstructing targetable pathways in lung Cancer by integrating diverse omics data</article-title><source>Nature Communications</source><volume>4</volume><elocation-id>2617</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms3617</pub-id><pub-id pub-id-type="pmid">24135919</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Comprehensive molecular profiling of lung adenocarcinoma</article-title><source>Nature</source><volume>511</volume><fpage>543</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/nature13385</pub-id><pub-id pub-id-type="pmid">25079552</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname> <given-names>DA</given-names></name><name><surname>Ashton</surname> <given-names>SE</given-names></name><name><surname>Ghiorghiu</surname> <given-names>S</given-names></name><name><surname>Eberlein</surname> <given-names>C</given-names></name><name><surname>Nebhan</surname> <given-names>CA</given-names></name><name><surname>Spitzler</surname> <given-names>PJ</given-names></name><name><surname>Orme</surname> <given-names>JP</given-names></name><name><surname>Finlay</surname> <given-names>MR</given-names></name><name><surname>Ward</surname> <given-names>RA</given-names></name><name><surname>Mellor</surname> <given-names>MJ</given-names></name><name><surname>Hughes</surname> <given-names>G</given-names></name><name><surname>Rahi</surname> <given-names>A</given-names></name><name><surname>Jacobs</surname> <given-names>VN</given-names></name><name><surname>Red Brewer</surname> <given-names>M</given-names></name><name><surname>Ichihara</surname> <given-names>E</given-names></name><name><surname>Sun</surname> <given-names>J</given-names></name><name><surname>Jin</surname> <given-names>H</given-names></name><name><surname>Ballard</surname> <given-names>P</given-names></name><name><surname>Al-Kadhimi</surname> <given-names>K</given-names></name><name><surname>Rowlinson</surname> <given-names>R</given-names></name><name><surname>Klinowska</surname> <given-names>T</given-names></name><name><surname>Richmond</surname> <given-names>GH</given-names></name><name><surname>Cantarini</surname> <given-names>M</given-names></name><name><surname>Kim</surname> <given-names>DW</given-names></name><name><surname>Ranson</surname> <given-names>MR</given-names></name><name><surname>Pao</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung Cancer</article-title><source>Cancer Discovery</source><volume>4</volume><fpage>1046</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-14-0337</pub-id><pub-id pub-id-type="pmid">24893891</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dance</surname> <given-names>M</given-names></name><name><surname>Montagner</surname> <given-names>A</given-names></name><name><surname>Salles</surname> <given-names>JP</given-names></name><name><surname>Yart</surname> <given-names>A</given-names></name><name><surname>Raynal</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The molecular functions of Shp2 in the ras/Mitogen-activated protein kinase (ERK1/2) pathway</article-title><source>Cellular Signalling</source><volume>20</volume><fpage>453</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2007.10.002</pub-id><pub-id pub-id-type="pmid">17993263</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Bruin</surname> <given-names>EC</given-names></name><name><surname>Cowell</surname> <given-names>C</given-names></name><name><surname>Warne</surname> <given-names>PH</given-names></name><name><surname>Jiang</surname> <given-names>M</given-names></name><name><surname>Saunders</surname> <given-names>RE</given-names></name><name><surname>Melnick</surname> <given-names>MA</given-names></name><name><surname>Gettinger</surname> <given-names>S</given-names></name><name><surname>Walther</surname> <given-names>Z</given-names></name><name><surname>Wurtz</surname> <given-names>A</given-names></name><name><surname>Heynen</surname> <given-names>GJ</given-names></name><name><surname>Heideman</surname> <given-names>DA</given-names></name><name><surname>Gómez-Román</surname> <given-names>J</given-names></name><name><surname>García-Castaño</surname> <given-names>A</given-names></name><name><surname>Gong</surname> <given-names>Y</given-names></name><name><surname>Ladanyi</surname> <given-names>M</given-names></name><name><surname>Varmus</surname> <given-names>H</given-names></name><name><surname>Bernards</surname> <given-names>R</given-names></name><name><surname>Smit</surname> <given-names>EF</given-names></name><name><surname>Politi</surname> <given-names>K</given-names></name><name><surname>Downward</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Reduced NF1 expression confers resistance to EGFR inhibition in lung Cancer</article-title><source>Cancer Discovery</source><volume>4</volume><fpage>606</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0741</pub-id><pub-id pub-id-type="pmid">24535670</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Della Corte</surname> <given-names>CM</given-names></name><name><surname>Ciaramella</surname> <given-names>V</given-names></name><name><surname>Cardone</surname> <given-names>C</given-names></name><name><surname>La Monica</surname> <given-names>S</given-names></name><name><surname>Alfieri</surname> <given-names>R</given-names></name><name><surname>Petronini</surname> <given-names>PG</given-names></name><name><surname>Malapelle</surname> <given-names>U</given-names></name><name><surname>Vigliar</surname> <given-names>E</given-names></name><name><surname>Pepe</surname> <given-names>F</given-names></name><name><surname>Troncone</surname> <given-names>G</given-names></name><name><surname>Castellone</surname> <given-names>MD</given-names></name><name><surname>Troiani</surname> <given-names>T</given-names></name><name><surname>Martinelli</surname> <given-names>E</given-names></name><name><surname>Ciardiello</surname> <given-names>F</given-names></name><name><surname>Morgillo</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Antitumor efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NCLC tumor models</article-title><source>Journal of Thoracic Oncology</source><volume>13</volume><fpage>810</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2018.02.025</pub-id><pub-id pub-id-type="pmid">29526823</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eberhard</surname> <given-names>DA</given-names></name><name><surname>Johnson</surname> <given-names>BE</given-names></name><name><surname>Amler</surname> <given-names>LC</given-names></name><name><surname>Goddard</surname> <given-names>AD</given-names></name><name><surname>Heldens</surname> <given-names>SL</given-names></name><name><surname>Herbst</surname> <given-names>RS</given-names></name><name><surname>Ince</surname> <given-names>WL</given-names></name><name><surname>Jänne</surname> <given-names>PA</given-names></name><name><surname>Januario</surname> <given-names>T</given-names></name><name><surname>Johnson</surname> <given-names>DH</given-names></name><name><surname>Klein</surname> <given-names>P</given-names></name><name><surname>Miller</surname> <given-names>VA</given-names></name><name><surname>Ostland</surname> <given-names>MA</given-names></name><name><surname>Ramies</surname> <given-names>DA</given-names></name><name><surname>Sebisanovic</surname> <given-names>D</given-names></name><name><surname>Stinson</surname> <given-names>JA</given-names></name><name><surname>Zhang</surname> <given-names>YR</given-names></name><name><surname>Seshagiri</surname> <given-names>S</given-names></name><name><surname>Hillan</surname> <given-names>KJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung Cancer treated with chemotherapy alone and in combination with erlotinib</article-title><source>Journal of Clinical Oncology</source><volume>23</volume><fpage>5900</fpage><lpage>5909</lpage><pub-id pub-id-type="doi">10.1200/JCO.2005.02.857</pub-id><pub-id pub-id-type="pmid">16043828</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eberlein</surname> <given-names>CA</given-names></name><name><surname>Stetson</surname> <given-names>D</given-names></name><name><surname>Markovets</surname> <given-names>AA</given-names></name><name><surname>Al-Kadhimi</surname> <given-names>KJ</given-names></name><name><surname>Lai</surname> <given-names>Z</given-names></name><name><surname>Fisher</surname> <given-names>PR</given-names></name><name><surname>Meador</surname> <given-names>CB</given-names></name><name><surname>Spitzler</surname> <given-names>P</given-names></name><name><surname>Ichihara</surname> <given-names>E</given-names></name><name><surname>Ross</surname> <given-names>SJ</given-names></name><name><surname>Ahdesmaki</surname> <given-names>MJ</given-names></name><name><surname>Ahmed</surname> <given-names>A</given-names></name><name><surname>Ratcliffe</surname> <given-names>LE</given-names></name><name><surname>O'Brien</surname> <given-names>EL</given-names></name><name><surname>Barnes</surname> <given-names>CH</given-names></name><name><surname>Brown</surname> <given-names>H</given-names></name><name><surname>Smith</surname> <given-names>PD</given-names></name><name><surname>Dry</surname> <given-names>JR</given-names></name><name><surname>Beran</surname> <given-names>G</given-names></name><name><surname>Thress</surname> <given-names>KS</given-names></name><name><surname>Dougherty</surname> <given-names>B</given-names></name><name><surname>Pao</surname> <given-names>W</given-names></name><name><surname>Cross</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Acquired resistance to the Mutant-Selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models</article-title><source>Cancer Research</source><volume>75</volume><fpage>2489</fpage><lpage>2500</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-3167</pub-id><pub-id pub-id-type="pmid">25870145</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekert</surname> <given-names>JE</given-names></name><name><surname>Johnson</surname> <given-names>K</given-names></name><name><surname>Strake</surname> <given-names>B</given-names></name><name><surname>Pardinas</surname> <given-names>J</given-names></name><name><surname>Jarantow</surname> <given-names>S</given-names></name><name><surname>Perkinson</surname> <given-names>R</given-names></name><name><surname>Colter</surname> <given-names>DC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro--implication for drug development</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e92248</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0092248</pub-id><pub-id pub-id-type="pmid">24638075</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelman</surname> <given-names>JA</given-names></name><name><surname>Mukohara</surname> <given-names>T</given-names></name><name><surname>Zejnullahu</surname> <given-names>K</given-names></name><name><surname>Lifshits</surname> <given-names>E</given-names></name><name><surname>Borrás</surname> <given-names>AM</given-names></name><name><surname>Gale</surname> <given-names>CM</given-names></name><name><surname>Naumov</surname> <given-names>GN</given-names></name><name><surname>Yeap</surname> <given-names>BY</given-names></name><name><surname>Jarrell</surname> <given-names>E</given-names></name><name><surname>Sun</surname> <given-names>J</given-names></name><name><surname>Tracy</surname> <given-names>S</given-names></name><name><surname>Zhao</surname> <given-names>X</given-names></name><name><surname>Heymach</surname> <given-names>JV</given-names></name><name><surname>Johnson</surname> <given-names>BE</given-names></name><name><surname>Cantley</surname> <given-names>LC</given-names></name><name><surname>Jänne</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung Cancer</article-title><source>Journal of Clinical Investigation</source><volume>116</volume><fpage>2695</fpage><lpage>2706</lpage><pub-id pub-id-type="doi">10.1172/JCI28656</pub-id><pub-id pub-id-type="pmid">16906227</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname> <given-names>R</given-names></name><name><surname>Kim</surname> <given-names>NG</given-names></name><name><surname>Gumbiner</surname> <given-names>BM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Regulation of hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1</article-title><source>PNAS</source><volume>110</volume><fpage>2569</fpage><lpage>2574</lpage><pub-id pub-id-type="doi">10.1073/pnas.1216462110</pub-id><pub-id pub-id-type="pmid">23359693</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fortian</surname> <given-names>A</given-names></name><name><surname>Sorkin</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Live-cell fluorescence imaging reveals high stoichiometry of Grb2 binding to the EGF receptor sustained during endocytosis</article-title><source>Journal of Cell Science</source><volume>127</volume><fpage>432</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1242/jcs.137786</pub-id><pub-id pub-id-type="pmid">24259669</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita-Sato</surname> <given-names>S</given-names></name><name><surname>Galeas</surname> <given-names>J</given-names></name><name><surname>Truitt</surname> <given-names>M</given-names></name><name><surname>Pitt</surname> <given-names>C</given-names></name><name><surname>Urisman</surname> <given-names>A</given-names></name><name><surname>Bandyopadhyay</surname> <given-names>S</given-names></name><name><surname>Ruggero</surname> <given-names>D</given-names></name><name><surname>McCormick</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Enhanced MET translation and signaling sustains K-Ras-Driven proliferation under Anchorage-Independent growth conditions</article-title><source>Cancer Research</source><volume>75</volume><fpage>2851</fpage><lpage>2862</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-1623</pub-id><pub-id pub-id-type="pmid">25977330</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname> <given-names>K</given-names></name><name><surname>Pierce</surname> <given-names>SE</given-names></name><name><surname>Li</surname> <given-names>A</given-names></name><name><surname>Spees</surname> <given-names>K</given-names></name><name><surname>Anderson</surname> <given-names>GR</given-names></name><name><surname>Seoane</surname> <given-names>JA</given-names></name><name><surname>Lo</surname> <given-names>YH</given-names></name><name><surname>Dubreuil</surname> <given-names>M</given-names></name><name><surname>Olivas</surname> <given-names>M</given-names></name><name><surname>Kamber</surname> <given-names>RA</given-names></name><name><surname>Wainberg</surname> <given-names>M</given-names></name><name><surname>Kostyrko</surname> <given-names>K</given-names></name><name><surname>Kelly</surname> <given-names>MR</given-names></name><name><surname>Yousefi</surname> <given-names>M</given-names></name><name><surname>Simpkins</surname> <given-names>SW</given-names></name><name><surname>Yao</surname> <given-names>D</given-names></name><name><surname>Lee</surname> <given-names>K</given-names></name><name><surname>Kuo</surname> <given-names>CJ</given-names></name><name><surname>Jackson</surname> <given-names>PK</given-names></name><name><surname>Sweet-Cordero</surname> <given-names>A</given-names></name><name><surname>Kundaje</surname> <given-names>A</given-names></name><name><surname>Gentles</surname> <given-names>AJ</given-names></name><name><surname>Curtis</surname> <given-names>C</given-names></name><name><surname>Winslow</surname> <given-names>MM</given-names></name><name><surname>Bassik</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>CRISPR screens in Cancer spheroids identify 3D growth-specific vulnerabilities</article-title><source>Nature</source><volume>580</volume><fpage>136</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2099-x</pub-id><pub-id pub-id-type="pmid">32238925</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname> <given-names>HX</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Liu</surname> <given-names>C</given-names></name><name><surname>Kovats</surname> <given-names>S</given-names></name><name><surname>Velazquez</surname> <given-names>R</given-names></name><name><surname>Lu</surname> <given-names>H</given-names></name><name><surname>Pant</surname> <given-names>B</given-names></name><name><surname>Shirley</surname> <given-names>M</given-names></name><name><surname>Meyer</surname> <given-names>MJ</given-names></name><name><surname>Pu</surname> <given-names>M</given-names></name><name><surname>Lim</surname> <given-names>J</given-names></name><name><surname>Fleming</surname> <given-names>M</given-names></name><name><surname>Alexander</surname> <given-names>L</given-names></name><name><surname>Farsidjani</surname> <given-names>A</given-names></name><name><surname>LaMarche</surname> <given-names>MJ</given-names></name><name><surname>Moody</surname> <given-names>S</given-names></name><name><surname>Silver</surname> <given-names>SJ</given-names></name><name><surname>Caponigro</surname> <given-names>G</given-names></name><name><surname>Stuart</surname> <given-names>DD</given-names></name><name><surname>Abrams</surname> <given-names>TJ</given-names></name><name><surname>Hammerman</surname> <given-names>PS</given-names></name><name><surname>Williams</surname> <given-names>J</given-names></name><name><surname>Engelman</surname> <given-names>JA</given-names></name><name><surname>Goldoni</surname> <given-names>S</given-names></name><name><surname>Mohseni</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS-Mutant cancers</article-title><source>Molecular Cancer Therapeutics</source><volume>18</volume><fpage>2368</fpage><lpage>2380</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-19-0170</pub-id><pub-id pub-id-type="pmid">31439712</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hillig</surname> <given-names>RC</given-names></name><name><surname>Sautier</surname> <given-names>B</given-names></name><name><surname>Schroeder</surname> <given-names>J</given-names></name><name><surname>Moosmayer</surname> <given-names>D</given-names></name><name><surname>Hilpmann</surname> <given-names>A</given-names></name><name><surname>Stegmann</surname> <given-names>CM</given-names></name><name><surname>Werbeck</surname> <given-names>ND</given-names></name><name><surname>Briem</surname> <given-names>H</given-names></name><name><surname>Boemer</surname> <given-names>U</given-names></name><name><surname>Weiske</surname> <given-names>J</given-names></name><name><surname>Badock</surname> <given-names>V</given-names></name><name><surname>Mastouri</surname> <given-names>J</given-names></name><name><surname>Petersen</surname> <given-names>K</given-names></name><name><surname>Siemeister</surname> <given-names>G</given-names></name><name><surname>Kahmann</surname> <given-names>JD</given-names></name><name><surname>Wegener</surname> <given-names>D</given-names></name><name><surname>Böhnke</surname> <given-names>N</given-names></name><name><surname>Eis</surname> <given-names>K</given-names></name><name><surname>Graham</surname> <given-names>K</given-names></name><name><surname>Wortmann</surname> <given-names>L</given-names></name><name><surname>von Nussbaum</surname> <given-names>F</given-names></name><name><surname>Bader</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction</article-title><source>PNAS</source><volume>116</volume><fpage>2551</fpage><lpage>2560</lpage><pub-id pub-id-type="doi">10.1073/pnas.1812963116</pub-id><pub-id pub-id-type="pmid">30683722</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hofmann</surname> <given-names>MH</given-names></name><name><surname>Gmachl</surname> <given-names>M</given-names></name><name><surname>Ramharter</surname> <given-names>J</given-names></name><name><surname>Savarese</surname> <given-names>F</given-names></name><name><surname>Gerlach</surname> <given-names>D</given-names></name><name><surname>Marszalek</surname> <given-names>JR</given-names></name><name><surname>Sanderson</surname> <given-names>MP</given-names></name><name><surname>Kessler</surname> <given-names>D</given-names></name><name><surname>Trapani</surname> <given-names>F</given-names></name><name><surname>Arnhof</surname> <given-names>H</given-names></name><name><surname>Rumpel</surname> <given-names>K</given-names></name><name><surname>Botesteanu</surname> <given-names>DA</given-names></name><name><surname>Ettmayer</surname> <given-names>P</given-names></name><name><surname>Gerstberger</surname> <given-names>T</given-names></name><name><surname>Kofink</surname> <given-names>C</given-names></name><name><surname>Wunberg</surname> <given-names>T</given-names></name><name><surname>Zoephel</surname> <given-names>A</given-names></name><name><surname>Fu</surname> <given-names>SC</given-names></name><name><surname>Teh</surname> <given-names>JL</given-names></name><name><surname>Bottcher</surname> <given-names>J</given-names></name><name><surname>Pototschnig</surname> <given-names>N</given-names></name><name><surname>Schachinger</surname> <given-names>F</given-names></name><name><surname>Schipany</surname> <given-names>K</given-names></name><name><surname>Lieb</surname> <given-names>S</given-names></name><name><surname>Vellano</surname> <given-names>CP</given-names></name><name><surname>O'Connell</surname> <given-names>JC</given-names></name><name><surname>Mendes</surname> <given-names>RL</given-names></name><name><surname>Moll</surname> <given-names>J</given-names></name><name><surname>Petronczki</surname> <given-names>M</given-names></name><name><surname>Heffernan</surname> <given-names>TP</given-names></name><name><surname>Pearson</surname> <given-names>M</given-names></name><name><surname>McConnell</surname> <given-names>DB</given-names></name><name><surname>Kraut</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition</article-title><source>Cancer Discovery</source><elocation-id>CD-20-0142</elocation-id><pub-id pub-id-type="doi">10.1158/2159-8290.CD-20-0142</pub-id><pub-id pub-id-type="pmid">32816843</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichihara</surname> <given-names>E</given-names></name><name><surname>Westover</surname> <given-names>D</given-names></name><name><surname>Meador</surname> <given-names>CB</given-names></name><name><surname>Yan</surname> <given-names>Y</given-names></name><name><surname>Bauer</surname> <given-names>JA</given-names></name><name><surname>Lu</surname> <given-names>P</given-names></name><name><surname>Ye</surname> <given-names>F</given-names></name><name><surname>Kulick</surname> <given-names>A</given-names></name><name><surname>de Stanchina</surname> <given-names>E</given-names></name><name><surname>McEwen</surname> <given-names>R</given-names></name><name><surname>Ladanyi</surname> <given-names>M</given-names></name><name><surname>Cross</surname> <given-names>D</given-names></name><name><surname>Pao</surname> <given-names>W</given-names></name><name><surname>Lovly</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>SFK/FAK signaling attenuates osimertinib efficacy in both Drug-Sensitive and Drug-Resistant models of EGFR-Mutant lung Cancer</article-title><source>Cancer Research</source><volume>77</volume><fpage>2990</fpage><lpage>3000</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-2300</pub-id><pub-id pub-id-type="pmid">28416483</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobi</surname> <given-names>N</given-names></name><name><surname>Seeboeck</surname> <given-names>R</given-names></name><name><surname>Hofmann</surname> <given-names>E</given-names></name><name><surname>Schweiger</surname> <given-names>H</given-names></name><name><surname>Smolinska</surname> <given-names>V</given-names></name><name><surname>Mohr</surname> <given-names>T</given-names></name><name><surname>Boyer</surname> <given-names>A</given-names></name><name><surname>Sommergruber</surname> <given-names>W</given-names></name><name><surname>Lechner</surname> <given-names>P</given-names></name><name><surname>Pichler-Huebschmann</surname> <given-names>C</given-names></name><name><surname>Önder</surname> <given-names>K</given-names></name><name><surname>Hundsberger</surname> <given-names>H</given-names></name><name><surname>Wiesner</surname> <given-names>C</given-names></name><name><surname>Eger</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Organotypic three-dimensional Cancer cell cultures mirror drug responses <italic>in vivo</italic>: lessons learned from the inhibition of EGFR signaling</article-title><source>Oncotarget</source><volume>8</volume><fpage>107423</fpage><lpage>107440</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.22475</pub-id><pub-id pub-id-type="pmid">29296175</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobsen</surname> <given-names>K</given-names></name><name><surname>Bertran-Alamillo</surname> <given-names>J</given-names></name><name><surname>Molina</surname> <given-names>MA</given-names></name><name><surname>Teixidó</surname> <given-names>C</given-names></name><name><surname>Karachaliou</surname> <given-names>N</given-names></name><name><surname>Pedersen</surname> <given-names>MH</given-names></name><name><surname>Castellví</surname> <given-names>J</given-names></name><name><surname>Garzón</surname> <given-names>M</given-names></name><name><surname>Codony-Servat</surname> <given-names>C</given-names></name><name><surname>Codony-Servat</surname> <given-names>J</given-names></name><name><surname>Giménez-Capitán</surname> <given-names>A</given-names></name><name><surname>Drozdowskyj</surname> <given-names>A</given-names></name><name><surname>Viteri</surname> <given-names>S</given-names></name><name><surname>Larsen</surname> <given-names>MR</given-names></name><name><surname>Lassen</surname> <given-names>U</given-names></name><name><surname>Felip</surname> <given-names>E</given-names></name><name><surname>Bivona</surname> <given-names>TG</given-names></name><name><surname>Ditzel</surname> <given-names>HJ</given-names></name><name><surname>Rosell</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Convergent akt activation drives acquired EGFR inhibitor resistance in lung Cancer</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>410</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-00450-6</pub-id><pub-id pub-id-type="pmid">28871105</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janes</surname> <given-names>KA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>An analysis of critical factors for quantitative immunoblotting</article-title><source>Science Signaling</source><volume>8</volume><elocation-id>rs2</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2005966</pub-id><pub-id pub-id-type="pmid">25852189</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janes</surname> <given-names>MR</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>LS</given-names></name><name><surname>Hansen</surname> <given-names>R</given-names></name><name><surname>Peters</surname> <given-names>U</given-names></name><name><surname>Guo</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Babbar</surname> <given-names>A</given-names></name><name><surname>Firdaus</surname> <given-names>SJ</given-names></name><name><surname>Darjania</surname> <given-names>L</given-names></name><name><surname>Feng</surname> <given-names>J</given-names></name><name><surname>Chen</surname> <given-names>JH</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Long</surname> <given-names>YO</given-names></name><name><surname>Thach</surname> <given-names>C</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Zarieh</surname> <given-names>A</given-names></name><name><surname>Ely</surname> <given-names>T</given-names></name><name><surname>Kucharski</surname> <given-names>JM</given-names></name><name><surname>Kessler</surname> <given-names>LV</given-names></name><name><surname>Wu</surname> <given-names>T</given-names></name><name><surname>Yu</surname> <given-names>K</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Yao</surname> <given-names>Y</given-names></name><name><surname>Deng</surname> <given-names>X</given-names></name><name><surname>Zarrinkar</surname> <given-names>PP</given-names></name><name><surname>Brehmer</surname> <given-names>D</given-names></name><name><surname>Dhanak</surname> <given-names>D</given-names></name><name><surname>Lorenzi</surname> <given-names>MV</given-names></name><name><surname>Hu-Lowe</surname> <given-names>D</given-names></name><name><surname>Patricelli</surname> <given-names>MP</given-names></name><name><surname>Ren</surname> <given-names>P</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Targeting KRAS mutant cancers with a covalent G12C-Specific inhibitor</article-title><source>Cell</source><volume>172</volume><fpage>578</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.01.006</pub-id><pub-id pub-id-type="pmid">29373830</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jänne</surname> <given-names>PA</given-names></name><name><surname>Yang</surname> <given-names>JC</given-names></name><name><surname>Kim</surname> <given-names>DW</given-names></name><name><surname>Planchard</surname> <given-names>D</given-names></name><name><surname>Ohe</surname> <given-names>Y</given-names></name><name><surname>Ramalingam</surname> <given-names>SS</given-names></name><name><surname>Ahn</surname> <given-names>MJ</given-names></name><name><surname>Kim</surname> <given-names>SW</given-names></name><name><surname>Su</surname> <given-names>WC</given-names></name><name><surname>Horn</surname> <given-names>L</given-names></name><name><surname>Haggstrom</surname> <given-names>D</given-names></name><name><surname>Felip</surname> <given-names>E</given-names></name><name><surname>Kim</surname> <given-names>JH</given-names></name><name><surname>Frewer</surname> <given-names>P</given-names></name><name><surname>Cantarini</surname> <given-names>M</given-names></name><name><surname>Brown</surname> <given-names>KH</given-names></name><name><surname>Dickinson</surname> <given-names>PA</given-names></name><name><surname>Ghiorghiu</surname> <given-names>S</given-names></name><name><surname>Ranson</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>AZD9291 in EGFR inhibitor-resistant non-small-cell lung Cancer</article-title><source>New England Journal of Medicine</source><volume>372</volume><fpage>1689</fpage><lpage>1699</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1411817</pub-id><pub-id pub-id-type="pmid">25923549</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeng</surname> <given-names>HH</given-names></name><name><surname>Taylor</surname> <given-names>LJ</given-names></name><name><surname>Bar-Sagi</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Sos-mediated cross-activation of wild-type ras by oncogenic ras is essential for tumorigenesis</article-title><source>Nature Communications</source><volume>3</volume><elocation-id>1168</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms2173</pub-id><pub-id pub-id-type="pmid">23132018</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimbo</surname> <given-names>T</given-names></name><name><surname>Hatanaka</surname> <given-names>M</given-names></name><name><surname>Komatsu</surname> <given-names>T</given-names></name><name><surname>Taira</surname> <given-names>T</given-names></name><name><surname>Kumazawa</surname> <given-names>K</given-names></name><name><surname>Maeda</surname> <given-names>N</given-names></name><name><surname>Suzuki</surname> <given-names>T</given-names></name><name><surname>Ota</surname> <given-names>M</given-names></name><name><surname>Haginoya</surname> <given-names>N</given-names></name><name><surname>Isoyama</surname> <given-names>T</given-names></name><name><surname>Fujiwara</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung Cancer xenograft model</article-title><source>Oncotarget</source><volume>10</volume><fpage>5152</fpage><lpage>5167</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.27114</pub-id><pub-id pub-id-type="pmid">31497246</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname> <given-names>GG</given-names></name><name><surname>Del Río</surname> <given-names>IB</given-names></name><name><surname>Sari</surname> <given-names>S</given-names></name><name><surname>Sekerim</surname> <given-names>A</given-names></name><name><surname>Young</surname> <given-names>LC</given-names></name><name><surname>Hartig</surname> <given-names>N</given-names></name><name><surname>Areso Zubiaur</surname> <given-names>I</given-names></name><name><surname>El-Bahrawy</surname> <given-names>MA</given-names></name><name><surname>Hynds</surname> <given-names>RE</given-names></name><name><surname>Lei</surname> <given-names>W</given-names></name><name><surname>Molina-Arcas</surname> <given-names>M</given-names></name><name><surname>Downward</surname> <given-names>J</given-names></name><name><surname>Rodriguez-Viciana</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2532</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10367-x</pub-id><pub-id pub-id-type="pmid">31182717</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>JW</given-names></name><name><surname>Ho</surname> <given-names>WJ</given-names></name><name><surname>Wu</surname> <given-names>BM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The role of the 3D environment in hypoxia-induced drug and apoptosis resistance</article-title><source>Anticancer Research</source><volume>31</volume><fpage>3237</fpage><lpage>3245</lpage><pub-id pub-id-type="pmid">21965731</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>D</given-names></name><name><surname>Bach</surname> <given-names>D-H</given-names></name><name><surname>Fan</surname> <given-names>Y-H</given-names></name><name><surname>Luu</surname> <given-names>T</given-names></name><name><surname>Hong</surname> <given-names>J-Y</given-names></name><name><surname>Park</surname> <given-names>HJ</given-names></name><name><surname>Lee</surname> <given-names>SK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung Cancer cells</article-title><source>Cell Death &amp; Disease</source><volume>10</volume><elocation-id>361</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-019-1601-6</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ku</surname> <given-names>BM</given-names></name><name><surname>Choi</surname> <given-names>MK</given-names></name><name><surname>Sun</surname> <given-names>JM</given-names></name><name><surname>Lee</surname> <given-names>SH</given-names></name><name><surname>Ahn</surname> <given-names>JS</given-names></name><name><surname>Park</surname> <given-names>K</given-names></name><name><surname>Ahn</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model</article-title><source>PLOS ONE</source><volume>13</volume><elocation-id>e0194730</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0194730</pub-id><pub-id pub-id-type="pmid">29641535</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurppa</surname> <given-names>KJ</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>To</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>Fan</surname> <given-names>M</given-names></name><name><surname>Vajdi</surname> <given-names>A</given-names></name><name><surname>Knelson</surname> <given-names>EH</given-names></name><name><surname>Xie</surname> <given-names>Y</given-names></name><name><surname>Lim</surname> <given-names>K</given-names></name><name><surname>Cejas</surname> <given-names>P</given-names></name><name><surname>Portell</surname> <given-names>A</given-names></name><name><surname>Lizotte</surname> <given-names>PH</given-names></name><name><surname>Ficarro</surname> <given-names>SB</given-names></name><name><surname>Li</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>T</given-names></name><name><surname>Haikala</surname> <given-names>HM</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Bahcall</surname> <given-names>M</given-names></name><name><surname>Gao</surname> <given-names>Y</given-names></name><name><surname>Shalhout</surname> <given-names>S</given-names></name><name><surname>Boettcher</surname> <given-names>S</given-names></name><name><surname>Shin</surname> <given-names>BH</given-names></name><name><surname>Thai</surname> <given-names>T</given-names></name><name><surname>Wilkens</surname> <given-names>MK</given-names></name><name><surname>Tillgren</surname> <given-names>ML</given-names></name><name><surname>Mushajiang</surname> <given-names>M</given-names></name><name><surname>Xu</surname> <given-names>M</given-names></name><name><surname>Choi</surname> <given-names>J</given-names></name><name><surname>Bertram</surname> <given-names>AA</given-names></name><name><surname>Ebert</surname> <given-names>BL</given-names></name><name><surname>Beroukhim</surname> <given-names>R</given-names></name><name><surname>Bandopadhayay</surname> <given-names>P</given-names></name><name><surname>Awad</surname> <given-names>MM</given-names></name><name><surname>Gokhale</surname> <given-names>PC</given-names></name><name><surname>Kirschmeier</surname> <given-names>PT</given-names></name><name><surname>Marto</surname> <given-names>JA</given-names></name><name><surname>Camargo</surname> <given-names>FD</given-names></name><name><surname>Haq</surname> <given-names>R</given-names></name><name><surname>Paweletz</surname> <given-names>CP</given-names></name><name><surname>Wong</surname> <given-names>K-K</given-names></name><name><surname>Barbie</surname> <given-names>DA</given-names></name><name><surname>Long</surname> <given-names>HW</given-names></name><name><surname>Gray</surname> <given-names>NS</given-names></name><name><surname>Jänne</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Treatment-Induced tumor dormancy through YAP-Mediated transcriptional reprogramming of the apoptotic pathway</article-title><source>Cancer Cell</source><volume>37</volume><fpage>104</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2019.12.006</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>La Monica</surname> <given-names>S</given-names></name><name><surname>Cretella</surname> <given-names>D</given-names></name><name><surname>Bonelli</surname> <given-names>M</given-names></name><name><surname>Fumarola</surname> <given-names>C</given-names></name><name><surname>Cavazzoni</surname> <given-names>A</given-names></name><name><surname>Digiacomo</surname> <given-names>G</given-names></name><name><surname>Flammini</surname> <given-names>L</given-names></name><name><surname>Barocelli</surname> <given-names>E</given-names></name><name><surname>Minari</surname> <given-names>R</given-names></name><name><surname>Naldi</surname> <given-names>N</given-names></name><name><surname>Petronini</surname> <given-names>PG</given-names></name><name><surname>Tiseo</surname> <given-names>M</given-names></name><name><surname>Alfieri</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines</article-title><source>Journal of Experimental &amp; Clinical Cancer Research</source><volume>36</volume><elocation-id>174</elocation-id><pub-id pub-id-type="doi">10.1186/s13046-017-0653-7</pub-id><pub-id pub-id-type="pmid">29202823</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamba</surname> <given-names>S</given-names></name><name><surname>Russo</surname> <given-names>M</given-names></name><name><surname>Sun</surname> <given-names>C</given-names></name><name><surname>Lazzari</surname> <given-names>L</given-names></name><name><surname>Cancelliere</surname> <given-names>C</given-names></name><name><surname>Grernrum</surname> <given-names>W</given-names></name><name><surname>Lieftink</surname> <given-names>C</given-names></name><name><surname>Bernards</surname> <given-names>R</given-names></name><name><surname>Di Nicolantonio</surname> <given-names>F</given-names></name><name><surname>Bardelli</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>RAF suppression synergizes with MEK inhibition in KRAS mutant Cancer cells</article-title><source>Cell Reports</source><volume>8</volume><fpage>1475</fpage><lpage>1483</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.07.033</pub-id><pub-id pub-id-type="pmid">25199829</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langhans</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Three-Dimensional <italic>in vitro</italic> Cell Culture Models in Drug Discovery and Drug Repositioning</article-title><source>Frontiers in Pharmacology</source><volume>9</volume><elocation-id>6</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2018.00006</pub-id><pub-id pub-id-type="pmid">29410625</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancini</surname> <given-names>M</given-names></name><name><surname>Gal</surname> <given-names>H</given-names></name><name><surname>Gaborit</surname> <given-names>N</given-names></name><name><surname>Mazzeo</surname> <given-names>L</given-names></name><name><surname>Romaniello</surname> <given-names>D</given-names></name><name><surname>Salame</surname> <given-names>TM</given-names></name><name><surname>Lindzen</surname> <given-names>M</given-names></name><name><surname>Mahlknecht</surname> <given-names>G</given-names></name><name><surname>Enuka</surname> <given-names>Y</given-names></name><name><surname>Burton</surname> <given-names>DG</given-names></name><name><surname>Roth</surname> <given-names>L</given-names></name><name><surname>Noronha</surname> <given-names>A</given-names></name><name><surname>Marrocco</surname> <given-names>I</given-names></name><name><surname>Adreka</surname> <given-names>D</given-names></name><name><surname>Altstadter</surname> <given-names>RE</given-names></name><name><surname>Bousquet</surname> <given-names>E</given-names></name><name><surname>Downward</surname> <given-names>J</given-names></name><name><surname>Maraver</surname> <given-names>A</given-names></name><name><surname>Krizhanovsky</surname> <given-names>V</given-names></name><name><surname>Yarden</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>An oligoclonal antibody durably overcomes resistance of lung Cancer to third-generation EGFR inhibitors</article-title><source>EMBO Molecular Medicine</source><volume>10</volume><fpage>294</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.15252/emmm.201708076</pub-id><pub-id pub-id-type="pmid">29212784</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCormick</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>KRAS as a therapeutic target</article-title><source>Clinical Cancer Research</source><volume>21</volume><fpage>1797</fpage><lpage>1801</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-2662</pub-id><pub-id pub-id-type="pmid">25878360</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittler</surname> <given-names>F</given-names></name><name><surname>Obeïd</surname> <given-names>P</given-names></name><name><surname>Rulina</surname> <given-names>AV</given-names></name><name><surname>Haguet</surname> <given-names>V</given-names></name><name><surname>Gidrol</surname> <given-names>X</given-names></name><name><surname>Balakirev</surname> <given-names>MY</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>High-Content monitoring of drug effects in a 3D spheroid model</article-title><source>Frontiers in Oncology</source><volume>7</volume><elocation-id>293</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2017.00293</pub-id><pub-id pub-id-type="pmid">29322028</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname> <given-names>TS</given-names></name><name><surname>Wu</surname> <given-names>YL</given-names></name><name><surname>Thongprasert</surname> <given-names>S</given-names></name><name><surname>Yang</surname> <given-names>CH</given-names></name><name><surname>Chu</surname> <given-names>DT</given-names></name><name><surname>Saijo</surname> <given-names>N</given-names></name><name><surname>Sunpaweravong</surname> <given-names>P</given-names></name><name><surname>Han</surname> <given-names>B</given-names></name><name><surname>Margono</surname> <given-names>B</given-names></name><name><surname>Ichinose</surname> <given-names>Y</given-names></name><name><surname>Nishiwaki</surname> <given-names>Y</given-names></name><name><surname>Ohe</surname> <given-names>Y</given-names></name><name><surname>Yang</surname> <given-names>JJ</given-names></name><name><surname>Chewaskulyong</surname> <given-names>B</given-names></name><name><surname>Jiang</surname> <given-names>H</given-names></name><name><surname>Duffield</surname> <given-names>EL</given-names></name><name><surname>Watkins</surname> <given-names>CL</given-names></name><name><surname>Armour</surname> <given-names>AA</given-names></name><name><surname>Fukuoka</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma</article-title><source>New England Journal of Medicine</source><volume>361</volume><fpage>947</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0810699</pub-id><pub-id pub-id-type="pmid">19692680</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munoz</surname> <given-names>DM</given-names></name><name><surname>Cassiani</surname> <given-names>PJ</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Billy</surname> <given-names>E</given-names></name><name><surname>Korn</surname> <given-names>JM</given-names></name><name><surname>Jones</surname> <given-names>MD</given-names></name><name><surname>Golji</surname> <given-names>J</given-names></name><name><surname>Ruddy</surname> <given-names>DA</given-names></name><name><surname>Yu</surname> <given-names>K</given-names></name><name><surname>McAllister</surname> <given-names>G</given-names></name><name><surname>DeWeck</surname> <given-names>A</given-names></name><name><surname>Abramowski</surname> <given-names>D</given-names></name><name><surname>Wan</surname> <given-names>J</given-names></name><name><surname>Shirley</surname> <given-names>MD</given-names></name><name><surname>Neshat</surname> <given-names>SY</given-names></name><name><surname>Rakiec</surname> <given-names>D</given-names></name><name><surname>de Beaumont</surname> <given-names>R</given-names></name><name><surname>Weber</surname> <given-names>O</given-names></name><name><surname>Kauffmann</surname> <given-names>A</given-names></name><name><surname>McDonald</surname> <given-names>ER</given-names></name><name><surname>Keen</surname> <given-names>N</given-names></name><name><surname>Hofmann</surname> <given-names>F</given-names></name><name><surname>Sellers</surname> <given-names>WR</given-names></name><name><surname>Schmelzle</surname> <given-names>T</given-names></name><name><surname>Stegmeier</surname> <given-names>F</given-names></name><name><surname>Schlabach</surname> <given-names>MR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CRISPR screens provide a comprehensive assessment of Cancer vulnerabilities but generate False-Positive hits for highly amplified genomic regions</article-title><source>Cancer Discovery</source><volume>6</volume><fpage>900</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-16-0178</pub-id><pub-id pub-id-type="pmid">27260157</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Namba</surname> <given-names>K</given-names></name><name><surname>Shien</surname> <given-names>K</given-names></name><name><surname>Takahashi</surname> <given-names>Y</given-names></name><name><surname>Torigoe</surname> <given-names>H</given-names></name><name><surname>Sato</surname> <given-names>H</given-names></name><name><surname>Yoshioka</surname> <given-names>T</given-names></name><name><surname>Takeda</surname> <given-names>T</given-names></name><name><surname>Kurihara</surname> <given-names>E</given-names></name><name><surname>Ogoshi</surname> <given-names>Y</given-names></name><name><surname>Yamamoto</surname> <given-names>H</given-names></name><name><surname>Soh</surname> <given-names>J</given-names></name><name><surname>Tomida</surname> <given-names>S</given-names></name><name><surname>Toyooka</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Activation of AXL as a preclinical acquired resistance mechanism against osimertinib treatment in <italic>EGFR</italic>-Mutant Non-Small Cell Lung Cancer Cells</article-title><source>Molecular Cancer Research</source><volume>17</volume><fpage>499</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-18-0628</pub-id><pub-id pub-id-type="pmid">30463991</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname> <given-names>RJ</given-names></name><name><surname>Haderk</surname> <given-names>F</given-names></name><name><surname>Stahlhut</surname> <given-names>C</given-names></name><name><surname>Schulze</surname> <given-names>CJ</given-names></name><name><surname>Hemmati</surname> <given-names>G</given-names></name><name><surname>Wildes</surname> <given-names>D</given-names></name><name><surname>Tzitzilonis</surname> <given-names>C</given-names></name><name><surname>Mordec</surname> <given-names>K</given-names></name><name><surname>Marquez</surname> <given-names>A</given-names></name><name><surname>Romero</surname> <given-names>J</given-names></name><name><surname>Hsieh</surname> <given-names>T</given-names></name><name><surname>Zaman</surname> <given-names>A</given-names></name><name><surname>Olivas</surname> <given-names>V</given-names></name><name><surname>McCoach</surname> <given-names>C</given-names></name><name><surname>Blakely</surname> <given-names>CM</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Kiss</surname> <given-names>G</given-names></name><name><surname>Koltun</surname> <given-names>ES</given-names></name><name><surname>Gill</surname> <given-names>AL</given-names></name><name><surname>Singh</surname> <given-names>M</given-names></name><name><surname>Goldsmith</surname> <given-names>MA</given-names></name><name><surname>Smith</surname> <given-names>JAM</given-names></name><name><surname>Bivona</surname> <given-names>TG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers</article-title><source>Nature Cell Biology</source><volume>20</volume><fpage>1064</fpage><lpage>1073</lpage><pub-id pub-id-type="doi">10.1038/s41556-018-0169-1</pub-id><pub-id pub-id-type="pmid">30104724</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunes</surname> <given-names>AS</given-names></name><name><surname>Barros</surname> <given-names>AS</given-names></name><name><surname>Costa</surname> <given-names>EC</given-names></name><name><surname>Moreira</surname> <given-names>AF</given-names></name><name><surname>Correia</surname> <given-names>IJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>3d tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs</article-title><source>Biotechnology and Bioengineering</source><volume>116</volume><fpage>206</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1002/bit.26845</pub-id><pub-id pub-id-type="pmid">30367820</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>JH</given-names></name><name><surname>Choi</surname> <given-names>YJ</given-names></name><name><surname>Kim</surname> <given-names>SY</given-names></name><name><surname>Lee</surname> <given-names>JE</given-names></name><name><surname>Sung</surname> <given-names>KJ</given-names></name><name><surname>Park</surname> <given-names>S</given-names></name><name><surname>Kim</surname> <given-names>WS</given-names></name><name><surname>Song</surname> <given-names>JS</given-names></name><name><surname>Choi</surname> <given-names>CM</given-names></name><name><surname>Sung</surname> <given-names>YH</given-names></name><name><surname>Rho</surname> <given-names>JK</given-names></name><name><surname>Lee</surname> <given-names>JC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung Cancer</article-title><source>Oncotarget</source><volume>7</volume><fpage>22005</fpage><lpage>22015</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.8013</pub-id><pub-id pub-id-type="pmid">26980747</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramalingam</surname> <given-names>SS</given-names></name><name><surname>Vansteenkiste</surname> <given-names>J</given-names></name><name><surname>Planchard</surname> <given-names>D</given-names></name><name><surname>Cho</surname> <given-names>BC</given-names></name><name><surname>Gray</surname> <given-names>JE</given-names></name><name><surname>Ohe</surname> <given-names>Y</given-names></name><name><surname>Zhou</surname> <given-names>C</given-names></name><name><surname>Reungwetwattana</surname> <given-names>T</given-names></name><name><surname>Cheng</surname> <given-names>Y</given-names></name><name><surname>Chewaskulyong</surname> <given-names>B</given-names></name><name><surname>Shah</surname> <given-names>R</given-names></name><name><surname>Cobo</surname> <given-names>M</given-names></name><name><surname>Lee</surname> <given-names>KH</given-names></name><name><surname>Cheema</surname> <given-names>P</given-names></name><name><surname>Tiseo</surname> <given-names>M</given-names></name><name><surname>John</surname> <given-names>T</given-names></name><name><surname>Lin</surname> <given-names>MC</given-names></name><name><surname>Imamura</surname> <given-names>F</given-names></name><name><surname>Kurata</surname> <given-names>T</given-names></name><name><surname>Todd</surname> <given-names>A</given-names></name><name><surname>Hodge</surname> <given-names>R</given-names></name><name><surname>Saggese</surname> <given-names>M</given-names></name><name><surname>Rukazenkov</surname> <given-names>Y</given-names></name><name><surname>Soria</surname> <given-names>JC</given-names></name><collab>FLAURA Investigators</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Overall survival with osimertinib in Untreated, <italic>EGFR</italic>-Mutated Advanced NSCLC</article-title><source>New England Journal of Medicine</source><volume>382</volume><fpage>41</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1913662</pub-id><pub-id pub-id-type="pmid">31751012</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riedl</surname> <given-names>A</given-names></name><name><surname>Schlederer</surname> <given-names>M</given-names></name><name><surname>Pudelko</surname> <given-names>K</given-names></name><name><surname>Stadler</surname> <given-names>M</given-names></name><name><surname>Walter</surname> <given-names>S</given-names></name><name><surname>Unterleuthner</surname> <given-names>D</given-names></name><name><surname>Unger</surname> <given-names>C</given-names></name><name><surname>Kramer</surname> <given-names>N</given-names></name><name><surname>Hengstschläger</surname> <given-names>M</given-names></name><name><surname>Kenner</surname> <given-names>L</given-names></name><name><surname>Pfeiffer</surname> <given-names>D</given-names></name><name><surname>Krupitza</surname> <given-names>G</given-names></name><name><surname>Dolznig</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Comparison of Cancer cells in 2D vs 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses</article-title><source>Journal of Cell Science</source><volume>130</volume><fpage>203</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1242/jcs.188102</pub-id><pub-id pub-id-type="pmid">27663511</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roell</surname> <given-names>KR</given-names></name><name><surname>Reif</surname> <given-names>DM</given-names></name><name><surname>Motsinger-Reif</surname> <given-names>AA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>An introduction to terminology and methodology of chemical Synergy-Perspectives from across disciplines</article-title><source>Frontiers in Pharmacology</source><volume>8</volume><elocation-id>158</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2017.00158</pub-id><pub-id pub-id-type="pmid">28473769</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romaniello</surname> <given-names>D</given-names></name><name><surname>Mazzeo</surname> <given-names>L</given-names></name><name><surname>Mancini</surname> <given-names>M</given-names></name><name><surname>Marrocco</surname> <given-names>I</given-names></name><name><surname>Noronha</surname> <given-names>A</given-names></name><name><surname>Kreitman</surname> <given-names>M</given-names></name><name><surname>Srivastava</surname> <given-names>S</given-names></name><name><surname>Ghosh</surname> <given-names>S</given-names></name><name><surname>Lindzen</surname> <given-names>M</given-names></name><name><surname>Salame</surname> <given-names>TM</given-names></name><name><surname>Onn</surname> <given-names>A</given-names></name><name><surname>Bar</surname> <given-names>J</given-names></name><name><surname>Yarden</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A combination of approved antibodies overcomes resistance of lung Cancer to osimertinib by blocking bypass pathways</article-title><source>Clinical Cancer Research</source><volume>24</volume><fpage>5610</fpage><lpage>5621</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-0450</pub-id><pub-id pub-id-type="pmid">29967248</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rotem</surname> <given-names>A</given-names></name><name><surname>Janzer</surname> <given-names>A</given-names></name><name><surname>Izar</surname> <given-names>B</given-names></name><name><surname>Ji</surname> <given-names>Z</given-names></name><name><surname>Doench</surname> <given-names>JG</given-names></name><name><surname>Garraway</surname> <given-names>LA</given-names></name><name><surname>Struhl</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation</article-title><source>PNAS</source><volume>112</volume><fpage>5708</fpage><lpage>5713</lpage><pub-id pub-id-type="doi">10.1073/pnas.1505979112</pub-id><pub-id pub-id-type="pmid">25902495</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanjana</surname> <given-names>NE</given-names></name><name><surname>Shalem</surname> <given-names>O</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Improved vectors and genome-wide libraries for CRISPR screening</article-title><source>Nature Methods</source><volume>11</volume><fpage>783</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3047</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholl</surname> <given-names>C</given-names></name><name><surname>Fröhling</surname> <given-names>S</given-names></name><name><surname>Dunn</surname> <given-names>IF</given-names></name><name><surname>Schinzel</surname> <given-names>AC</given-names></name><name><surname>Barbie</surname> <given-names>DA</given-names></name><name><surname>Kim</surname> <given-names>SY</given-names></name><name><surname>Silver</surname> <given-names>SJ</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name><name><surname>Wadlow</surname> <given-names>RC</given-names></name><name><surname>Ramaswamy</surname> <given-names>S</given-names></name><name><surname>Döhner</surname> <given-names>K</given-names></name><name><surname>Bullinger</surname> <given-names>L</given-names></name><name><surname>Sandy</surname> <given-names>P</given-names></name><name><surname>Boehm</surname> <given-names>JS</given-names></name><name><surname>Root</surname> <given-names>DE</given-names></name><name><surname>Jacks</surname> <given-names>T</given-names></name><name><surname>Hahn</surname> <given-names>WC</given-names></name><name><surname>Gilliland</surname> <given-names>DG</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human Cancer cells</article-title><source>Cell</source><volume>137</volume><fpage>821</fpage><lpage>834</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.03.017</pub-id><pub-id pub-id-type="pmid">19490892</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheffels</surname> <given-names>E</given-names></name><name><surname>Sealover</surname> <given-names>NE</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Kim</surname> <given-names>DH</given-names></name><name><surname>Vazirani</surname> <given-names>IA</given-names></name><name><surname>Lee</surname> <given-names>E</given-names></name><name><surname>M Terrell</surname> <given-names>E</given-names></name><name><surname>Morrison</surname> <given-names>DK</given-names></name><name><surname>Luo</surname> <given-names>J</given-names></name><name><surname>Kortum</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation</article-title><source>Science Signaling</source><volume>11</volume><elocation-id>eaar8371</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aar8371</pub-id><pub-id pub-id-type="pmid">30181243</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheffels</surname> <given-names>E</given-names></name><name><surname>Sealover</surname> <given-names>NE</given-names></name><name><surname>Theard</surname> <given-names>PL</given-names></name><name><surname>Kortum</surname> <given-names>RL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in <italic>RAS</italic> -mutant cancer cells</article-title><source>Small GTPases</source><volume>2</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1080/21541248.2019.1611168</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>P</given-names></name><name><surname>Oh</surname> <given-names>YT</given-names></name><name><surname>Zhang</surname> <given-names>G</given-names></name><name><surname>Yao</surname> <given-names>W</given-names></name><name><surname>Yue</surname> <given-names>P</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Kanteti</surname> <given-names>R</given-names></name><name><surname>Riehm</surname> <given-names>J</given-names></name><name><surname>Salgia</surname> <given-names>R</given-names></name><name><surname>Owonikoko</surname> <given-names>TK</given-names></name><name><surname>Ramalingam</surname> <given-names>SS</given-names></name><name><surname>Chen</surname> <given-names>M</given-names></name><name><surname>Sun</surname> <given-names>SY</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung Cancer treatment</article-title><source>Cancer Letters</source><volume>380</volume><fpage>494</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2016.07.021</pub-id><pub-id pub-id-type="pmid">27450722</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname> <given-names>P</given-names></name><name><surname>Oh</surname> <given-names>YT</given-names></name><name><surname>Deng</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>G</given-names></name><name><surname>Qian</surname> <given-names>G</given-names></name><name><surname>Zhang</surname> <given-names>S</given-names></name><name><surname>Ren</surname> <given-names>H</given-names></name><name><surname>Wu</surname> <given-names>G</given-names></name><name><surname>Legendre</surname> <given-names>B</given-names></name><name><surname>Anderson</surname> <given-names>E</given-names></name><name><surname>Ramalingam</surname> <given-names>SS</given-names></name><name><surname>Owonikoko</surname> <given-names>TK</given-names></name><name><surname>Chen</surname> <given-names>M</given-names></name><name><surname>Sun</surname> <given-names>SY</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Overcoming acquired resistance to AZD9291, A Third-Generation EGFR inhibitor, through modulation of MEK/ERK-Dependent bim and Mcl-1 degradation</article-title><source>Clinical Cancer Research</source><volume>23</volume><fpage>6567</fpage><lpage>6579</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-1574</pub-id><pub-id pub-id-type="pmid">28765329</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname> <given-names>A</given-names></name><name><surname>Greninger</surname> <given-names>P</given-names></name><name><surname>Rhodes</surname> <given-names>D</given-names></name><name><surname>Koopman</surname> <given-names>L</given-names></name><name><surname>Violette</surname> <given-names>S</given-names></name><name><surname>Bardeesy</surname> <given-names>N</given-names></name><name><surname>Settleman</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A gene expression signature associated with &quot;K-Ras addiction&quot; reveals regulators of EMT and tumor cell survival</article-title><source>Cancer Cell</source><volume>15</volume><fpage>489</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2009.03.022</pub-id><pub-id pub-id-type="pmid">19477428</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname> <given-names>A</given-names></name><name><surname>Sweeney</surname> <given-names>MF</given-names></name><name><surname>Yu</surname> <given-names>M</given-names></name><name><surname>Burger</surname> <given-names>A</given-names></name><name><surname>Greninger</surname> <given-names>P</given-names></name><name><surname>Benes</surname> <given-names>C</given-names></name><name><surname>Haber</surname> <given-names>DA</given-names></name><name><surname>Settleman</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>TAK1 inhibition promotes apoptosis in KRAS-dependent Colon cancers</article-title><source>Cell</source><volume>148</volume><fpage>639</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.12.033</pub-id><pub-id pub-id-type="pmid">22341439</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soria</surname> <given-names>JC</given-names></name><name><surname>Ohe</surname> <given-names>Y</given-names></name><name><surname>Vansteenkiste</surname> <given-names>J</given-names></name><name><surname>Reungwetwattana</surname> <given-names>T</given-names></name><name><surname>Chewaskulyong</surname> <given-names>B</given-names></name><name><surname>Lee</surname> <given-names>KH</given-names></name><name><surname>Dechaphunkul</surname> <given-names>A</given-names></name><name><surname>Imamura</surname> <given-names>F</given-names></name><name><surname>Nogami</surname> <given-names>N</given-names></name><name><surname>Kurata</surname> <given-names>T</given-names></name><name><surname>Okamoto</surname> <given-names>I</given-names></name><name><surname>Zhou</surname> <given-names>C</given-names></name><name><surname>Cho</surname> <given-names>BC</given-names></name><name><surname>Cheng</surname> <given-names>Y</given-names></name><name><surname>Cho</surname> <given-names>EK</given-names></name><name><surname>Voon</surname> <given-names>PJ</given-names></name><name><surname>Planchard</surname> <given-names>D</given-names></name><name><surname>Su</surname> <given-names>WC</given-names></name><name><surname>Gray</surname> <given-names>JE</given-names></name><name><surname>Lee</surname> <given-names>SM</given-names></name><name><surname>Hodge</surname> <given-names>R</given-names></name><name><surname>Marotti</surname> <given-names>M</given-names></name><name><surname>Rukazenkov</surname> <given-names>Y</given-names></name><name><surname>Ramalingam</surname> <given-names>SS</given-names></name><collab>FLAURA Investigators</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Osimertinib in untreated <italic>EGFR</italic>-Mutated advanced Non-Small-Cell lung Cancer</article-title><source>The New England Journal of Medicine</source><volume>378</volume><fpage>113</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1713137</pub-id><pub-id pub-id-type="pmid">29151359</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tallarida</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Quantitative methods for assessing drug synergism</article-title><source>Genes &amp; Cancer</source><volume>2</volume><fpage>1003</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1177/1947601912440575</pub-id><pub-id pub-id-type="pmid">22737266</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname> <given-names>H</given-names></name><name><surname>Yamada</surname> <given-names>T</given-names></name><name><surname>Wang</surname> <given-names>R</given-names></name><name><surname>Tanimura</surname> <given-names>K</given-names></name><name><surname>Adachi</surname> <given-names>Y</given-names></name><name><surname>Nishiyama</surname> <given-names>A</given-names></name><name><surname>Tanimoto</surname> <given-names>A</given-names></name><name><surname>Takeuchi</surname> <given-names>S</given-names></name><name><surname>Araujo</surname> <given-names>LH</given-names></name><name><surname>Boroni</surname> <given-names>M</given-names></name><name><surname>Yoshimura</surname> <given-names>A</given-names></name><name><surname>Shiotsu</surname> <given-names>S</given-names></name><name><surname>Matsumoto</surname> <given-names>I</given-names></name><name><surname>Watanabe</surname> <given-names>S</given-names></name><name><surname>Kikuchi</surname> <given-names>T</given-names></name><name><surname>Miura</surname> <given-names>S</given-names></name><name><surname>Tanaka</surname> <given-names>H</given-names></name><name><surname>Kitazaki</surname> <given-names>T</given-names></name><name><surname>Yamaguchi</surname> <given-names>H</given-names></name><name><surname>Mukae</surname> <given-names>H</given-names></name><name><surname>Uchino</surname> <given-names>J</given-names></name><name><surname>Uehara</surname> <given-names>H</given-names></name><name><surname>Takayama</surname> <given-names>K</given-names></name><name><surname>Yano</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>259</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-08074-0</pub-id><pub-id pub-id-type="pmid">30651547</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tricker</surname> <given-names>EM</given-names></name><name><surname>Xu</surname> <given-names>C</given-names></name><name><surname>Uddin</surname> <given-names>S</given-names></name><name><surname>Capelletti</surname> <given-names>M</given-names></name><name><surname>Ercan</surname> <given-names>D</given-names></name><name><surname>Ogino</surname> <given-names>A</given-names></name><name><surname>Pratilas</surname> <given-names>CA</given-names></name><name><surname>Rosen</surname> <given-names>N</given-names></name><name><surname>Gray</surname> <given-names>NS</given-names></name><name><surname>Wong</surname> <given-names>KK</given-names></name><name><surname>Jänne</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR-Mutant lung Cancer</article-title><source>Cancer Discovery</source><volume>5</volume><fpage>960</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-0063</pub-id><pub-id pub-id-type="pmid">26036643</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tumaneng</surname> <given-names>K</given-names></name><name><surname>Schlegelmilch</surname> <given-names>K</given-names></name><name><surname>Russell</surname> <given-names>RC</given-names></name><name><surname>Yimlamai</surname> <given-names>D</given-names></name><name><surname>Basnet</surname> <given-names>H</given-names></name><name><surname>Mahadevan</surname> <given-names>N</given-names></name><name><surname>Fitamant</surname> <given-names>J</given-names></name><name><surname>Bardeesy</surname> <given-names>N</given-names></name><name><surname>Camargo</surname> <given-names>FD</given-names></name><name><surname>Guan</surname> <given-names>KL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>YAP mediates crosstalk between the hippo and PI(3)K–TOR pathways by suppressing PTEN via miR-29</article-title><source>Nature Cell Biology</source><volume>14</volume><fpage>1322</fpage><lpage>1329</lpage><pub-id pub-id-type="doi">10.1038/ncb2615</pub-id><pub-id pub-id-type="pmid">23143395</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vigil</surname> <given-names>D</given-names></name><name><surname>Cherfils</surname> <given-names>J</given-names></name><name><surname>Rossman</surname> <given-names>KL</given-names></name><name><surname>Der</surname> <given-names>CJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Ras superfamily GEFs and GAPs: validated and tractable targets for Cancer therapy?</article-title><source>Nature Reviews Cancer</source><volume>10</volume><fpage>842</fpage><lpage>857</lpage><pub-id pub-id-type="doi">10.1038/nrc2960</pub-id><pub-id pub-id-type="pmid">21102635</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname> <given-names>S</given-names></name><name><surname>Yoshida</surname> <given-names>T</given-names></name><name><surname>Kawakami</surname> <given-names>H</given-names></name><name><surname>Takegawa</surname> <given-names>N</given-names></name><name><surname>Tanizaki</surname> <given-names>J</given-names></name><name><surname>Hayashi</surname> <given-names>H</given-names></name><name><surname>Takeda</surname> <given-names>M</given-names></name><name><surname>Yonesaka</surname> <given-names>K</given-names></name><name><surname>Tsurutani</surname> <given-names>J</given-names></name><name><surname>Nakagawa</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>T790M-Selective EGFR-TKI combined with dasatinib as an optimal strategy for overcoming EGFR-TKI resistance in T790M-Positive Non-Small cell lung Cancer</article-title><source>Molecular Cancer Therapeutics</source><volume>16</volume><fpage>2563</fpage><lpage>2571</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-17-0351</pub-id><pub-id pub-id-type="pmid">28839001</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname> <given-names>H</given-names></name><name><surname>Dai</surname> <given-names>X</given-names></name><name><surname>Yu</surname> <given-names>H</given-names></name><name><surname>Zhou</surname> <given-names>S</given-names></name><name><surname>Fan</surname> <given-names>Z</given-names></name><name><surname>Wei</surname> <given-names>G</given-names></name><name><surname>Tang</surname> <given-names>Q</given-names></name><name><surname>Gong</surname> <given-names>Q</given-names></name><name><surname>Bi</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy</article-title><source>Cell Death &amp; Disease</source><volume>9</volume><elocation-id>269</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-018-0302-x</pub-id><pub-id pub-id-type="pmid">29449645</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>JJ</given-names></name><name><surname>Zhou</surname> <given-names>Q</given-names></name><name><surname>Yan</surname> <given-names>HH</given-names></name><name><surname>Zhang</surname> <given-names>XC</given-names></name><name><surname>Chen</surname> <given-names>HJ</given-names></name><name><surname>Tu</surname> <given-names>HY</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>Xu</surname> <given-names>CR</given-names></name><name><surname>Su</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>BC</given-names></name><name><surname>Jiang</surname> <given-names>BY</given-names></name><name><surname>Bai</surname> <given-names>XY</given-names></name><name><surname>Zhong</surname> <given-names>WZ</given-names></name><name><surname>Yang</surname> <given-names>XN</given-names></name><name><surname>Wu</surname> <given-names>YL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung Cancer with EGFR mutations</article-title><source>British Journal of Cancer</source><volume>116</volume><fpage>568</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1038/bjc.2016.456</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Jiang</surname> <given-names>G</given-names></name><name><surname>Yang</surname> <given-names>F</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Knockdown of mutant K-ras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung Cancer cells</article-title><source>Cancer Biology &amp; Therapy</source><volume>5</volume><fpage>1481</fpage><lpage>1486</lpage><pub-id pub-id-type="doi">10.4161/cbt.5.11.3297</pub-id><pub-id pub-id-type="pmid">17172815</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.58204.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Corey</surname><given-names>Seth J</given-names></name><role>Reviewing Editor</role><aff><institution>Cleveland Clinic</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Roose</surname><given-names>Jeroen P</given-names></name><role>Reviewer</role><aff><institution>University of California, San Francisco</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>One of the weaknesses of cell culture studies to screen for anti-neoplastic drugs is that they lack the three-dimensionality or architectural complexity of tumors. The novel spheroid-based studies on non-small cell lung cancer in this paper advance the design of molecular targeted therapies by combining EGF Receptor kinase inhibitors with compounds that abrogate SOS and SHP2 signaling.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Marked Synergy by Vertical Inhibition of EGFR signaling in NSCLC: SOS1 as a therapeutic target in EGFR-mutated cancer&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by four peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jonathan Cooper as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Jeroen P Roose (Reviewer #4).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as <italic>eLife</italic> papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.</p><p>Summary:</p><p>Resistance to first and second generation EGFR TKI's is a clinically important problem. 3D cultures have the advantage of more closely resembling in vivo biology without the need for time-consuming and resource intensive in vivo studies and therefore exploring therapeutic synergies in 3D culture conditions is a worthwhile objective. Overall your work is meritorious, the findings are interesting, results are presented in a convincing manner, and the conclusions are generally plausible.</p><p>Essential revisions:</p><p>While the reviewers suggested that your findings would be even stronger were in vivo data included to corroborate the 3D cultures and comparison made with 2D culture data so to demonstrate that signaling changes are 3D specific. Please address the comments below and incorporate them into the Discussion section.</p><p>Similarly, exploring the therapeutic potential of SOS1/2 represents a promising novel pathway for targeting EGFR-TKI resistance. The work is original and interesting. The study methodology is provided in sufficient detail to assess the scientific rigor of the experiments and subsequent analysis. The authors are to be commended on very well written manuscript without distracting typographical errors; the figures are appealing, sequenced appropriately, clearly explained, and helpful schematics are included (e.g. Figure 2A-D, Figure 7A).</p><p>1) The authors contend 3D culture is more representative of in vivo with respect to therapeutic responses (and provide references for this). However, as this contention (superiority of 3D culture) is a central pillar of their work, the manuscript would be strengthened if the mechanisms that drive selective sensitivity to SOS1 deletion in 3D cultures (Figure 1) and synergy with combination therapies (Figures 2 and 3) were more thoroughly explored or discussed.</p><p>2) No in vivo data to corroborate the more representative nature of the 3D cultures is provided. The inclusion of in vivo experimental data would address questions related to the possibility of artifact related to SOS knockout in 3D culture conditions and similarly as to whether synergy will persist with BAY-293 treatment in vivo.</p><p>3) SOS1 deletion 'completely inhibited spheroid growth in both H1975 cells' (Figure 1C). As such it is unclear how this model is subsequently used to established specificity of BAY-293 for SOS1 in 3D Cx models. The latter data seem to conflict with the former in that 3D growth under SOS1 KO conditions is relatively unaffected (Figure 1F, Figure 1—figure supplement 2).</p><p>4) Combined EGFR and SOS1 inhibition inhibited Raf/MEK/ERK and PI3K/AKT signaling in 3D culture, suggesting a mechanism for the observed growth effects (Figure 6). Unclear if these downstream signaling changes are unique to 3D culture conditions (no 2D data); possibly a missed opportunity to provide an interesting mechanism for selective sensitization in 3D conditions.</p><p>The authors found that knockout of SOS1 or treatment with SOS1 inhibitor reduced EGFR-mutated lung cancer cell proliferation in 3D spheroid culture but not in 2D culture. Then, they showed that osimertinib had synergistic effects on inhibition of the EGFR mutated lung cancer cell proliferation with SOS1 inhibitor. They used several cancer cell lines carrying gefitinib-sensitive mutations with or without resistance mutations. Then they examined whether synergistic effects are observed among several compounds including inhibitors for Shp2, MEK or PI3K. They found that the combination of osimertinib and SOS1 inhibitor or osimertinib and Shp2 inhibitor had synergistic effects.</p><p>5) The experiments are well-done. It is reasonable to use two methods (combination index and Bliss index) for calculating the synergistic effects to confirm the reproducibility of the results. They clearly showed the synergistic effects between osimertinib and SOS1 inhibitor or osimertinib and Shp2 inhibitor. However, all the experiments were done by using in vitro 3D spheroid culture model. It would be very important to confirm their results in vivo, if synergistic effects of these combinations of the drugs are observed in preclinical models by using mouse xenograft.</p><p>6) It is unclear why SOS1 inhibitor had effects in 3D culture but not in 2D culture. Please show findings related to the reasonable mechanisms or discuss the potential mechanisms at least why they obtained such results.</p><p>7) They used one kind of targeting sequences for SOS1 and SOS2. In order to exclude the possibility of off-target effects, please perform single-cell cloning to have several clones or generate several knockout cells by using at least 2 kinds of targeting sequences. If you have these data please add. If not, please be clear in the paper.</p><p>8) Do disparate 3D spheroid (and organoid) culture systems exist? If so, please briefly summarize the 3D spheroid methodology and rationale, including pros and cons relative to other 3D culture techniques, in the Results section. Alternatively, if one uniform 3D culture technique is consistently used for human NSCLC cell line studies, please explain in detail.</p><p>9) In the Discussion, please address limitations of the current study and future directions. For example, SOS1 inhibitor, BAY-293 is not suitable for in vivo studies, and the authors should be transparent about that limitation and suggest future directions accordingly. In the absence of animal studies, it is important to describe whether in vivo model studies are necessary for translational and clinical development of the proposed treatment strategy, including discussion within the context of the discussed clinical trials (Discussion, last paragraph).</p><p>10) The study lacks direct evidence that osimertinib and BAY-293 dual therapy prevents EGFR TKI-refractory lung cancer growth. For example, one could envision a study where osimertinib-sensitive cells are continuously treated with osimertinib +/- BAY-293 over time (similar to how EGFR TKI resistant cells are made) to determine whether the addition of BAY-293 delays or prevents osimertinib resistance. Please address.</p><p>The reported synergy between EGFR inhibition and BAY-293 (but also Shp2 inhibition and BAY-293) and the lack of synergy between EGFR inhibition and targeting of RAF-MEK-ERK or PI3K-AKT is very intriguing and begs the question whether other effector pathways downstream of Ras are engaged (Discussion, fifth paragraph).</p><p>11) What is lacking here is a RasGTP pull down with BAY-293. Even only one cell line with the nice combo of 2D versus 3D and WT versus SOS1 CRISPR would be very valuable. The drug is still relatively new (2019, PNAS) and some validation would be important.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.58204.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>While the reviewers suggested that your findings would be even stronger were in vivo data included to corroborate the 3D cultures and comparison made with 2D culture data so to demonstrate that signaling changes are 3D specific. Please address the comments below and incorporate them into the Discussion section.</p><p>Similarly, exploring the therapeutic potential of SOS1/2 represents a promising novel pathway for targeting EGFR-TKI resistance. The work is original and interesting. The study methodology is provided in sufficient detail to assess the scientific rigor of the experiments and subsequent analysis. The authors are to be commended on very well written manuscript without distracting typographical errors; the figures are appealing, sequenced appropriately, clearly explained, and helpful schematics are included (e.g. Figure 2A-D, Figure 7A).</p><p>1) The authors contend 3D culture is more representative of in vivo with respect to therapeutic responses (and provide references for this). However, as this contention (superiority of 3D culture) is a central pillar of their work, the manuscript would be strengthened if the mechanisms that drive selective sensitivity to SOS1 deletion in 3D cultures (Figure 1) and synergy with combination therapies (Figures 2 and 3) were more thoroughly explored or discussed.</p></disp-quote><p>A provisionally accepted publication from Boehringer Ingelheim at Cancer Discovery using their novel SOS1 inhibitor has corroborated the effect of SOS1 inhibition in 3D versus 2D culture (referenced). We have added text to the Discussion hypothesizing on the mechanism by which SOS1 inhibition or deletion is specifically important for 3D growth.</p><disp-quote content-type="editor-comment"><p>2) No in vivo data to corroborate the more representative nature of the 3D cultures is provided. The inclusion of in vivo experimental data would address questions related to the possibility of artifact related to SOS knockout in 3D culture conditions and similarly as to whether synergy will persist with BAY-293 treatment in vivo.</p></disp-quote><p>We appreciate the comment and agree that the next step is inhibiting SOS1 in vivo. Unfortunately, the tool compound BAY-293 is not suitable for in vivo studies due to bioavailability issues (Hillig et al., 2019). At the April AACR meeting, Marco Hoffman from Boehringer Ingelheim showed nice data on their orally available SOS1 inhibitors BI-3406 and BI-1701963, and a manuscript with these findings has been provisionally accepted at Cancer Discovery. We reference this manuscript, and look forward to testing these inhibitors and further using them inhibitors for in vivo studies once they are available.</p><p>We have added text to the Discussion to help clarify that BAY-293 could not be used for in vivo studies, and have referenced a recently accepted publication from Boehringer Ingelheim in Cancer Discovery (see below) describing their novel SOS1 inhibitors that are bioavailable in vivo.</p><disp-quote content-type="editor-comment"><p>3) SOS1 deletion 'completely inhibited spheroid growth in both H1975 cells' (Figure 1C). As such it is unclear how this model is subsequently used to established specificity of BAY-293 for SOS1 in 3D Cx models. The latter data seem to conflict with the former in that 3D growth under SOS1 KO conditions is relatively unaffected (Figure 1F, Figure 1—figure supplement 2).</p></disp-quote><p>We appreciate the comment and understand the confusion that our data normalization in Figure 1F and Figure 1—figure supplement 2 has caused. For Figure 1C, it is true that SOS1 deletion inhibited oncogenic transformation. In Figure 1F and Figure 1—figure supplement 2, we set the untreated sample for each individual cell line to 100%, and have reported the dose response curves relative to the untreated sample for each condition (NT vs. SOS1 KO vs. SOS2 KO). We have clarified this in the text, legends, and Materials and methods. Further, in both 1975 and 3255 cells, we do not see drastic 3D growth differences at 4 days in NT vs. SOS1 KO cells, so differences in the ‘baseline’ would not be expected.</p><disp-quote content-type="editor-comment"><p>4) Combined EGFR and SOS1 inhibition inhibited Raf/MEK/ERK and PI3K/AKT signaling in 3D culture, suggesting a mechanism for the observed growth effects (Figure 6). Unclear if these downstream signaling changes are unique to 3D culture conditions (no 2D data); possibly a missed opportunity to provide an interesting mechanism for selective sensitization in 3D conditions.</p></disp-quote><p>We appreciate the reviewer comments, and agree that these studies would be interesting. Unfortunately, we focused our studies early on to 3D culture, and do not have equivalent 2D signaling data to add to the current study. We like this premise, and will investigate the idea in future experiments. We hypothesize that the difference are not due to intrinsic differences to signaling responses to SOS1 inhibition in 2D vs. 3D, but rather to the cell’s need for PI3K signaling for protection from anoikis in 3D culture.</p><disp-quote content-type="editor-comment"><p>The authors found that knockout of SOS1 or treatment with SOS1 inhibitor reduced EGFR-mutated lung cancer cell proliferation in 3D spheroid culture but not in 2D culture. Then, they showed that osimertinib had synergistic effects on inhibition of the EGFR mutated lung cancer cell proliferation with SOS1 inhibitor. They used several cancer cell lines carrying gefitinib-sensitive mutations with or without resistance mutations. Then they examined whether synergistic effects are observed among several compounds including inhibitors for Shp2, MEK or PI3K. They found that the combination of osimertinib and SOS1 inhibitor or osimertinib and Shp2 inhibitor had synergistic effects.</p></disp-quote><p>We thank the reviewer for the kind comment.</p><disp-quote content-type="editor-comment"><p>5) The experiments are well-done. It is reasonable to use two methods (combination index and Bliss index) for calculating the synergistic effects to confirm the reproducibility of the results. They clearly showed the synergistic effects between osimertinib and SOS1 inhibitor or osimertinib and Shp2 inhibitor. However, all the experiments were done by using in vitro 3D spheroid culture model. It would be very important to confirm their results in vivo, if synergistic effects of these combinations of the drugs are observed in preclinical models by using mouse xenograft.</p></disp-quote><p>We appreciate the comment and agree that the next step is inhibiting SOS1 in vivo. Unfortunately, the tool compound BAY-293 is not suitable for in vivo studies due to bioavailability issues (Hillig et al., 2019). At the April AACR meeting, Marco Hoffman from Boehringer Ingelheim showed nice data on their orally available SOS1 inhibitors BI-3406 and BI-1701963, and this manuscript has been provisionally accepted at Cancer Discovery (they are submitting second revisions next week). We look forward to testing these inhibitors and further using them inhibitors for in vivo studies once they are published.</p><disp-quote content-type="editor-comment"><p>6) It is unclear why SOS1 inhibitor had effects in 3D culture but not in 2D culture. Please show findings related to the reasonable mechanisms or discuss the potential mechanisms at least why they obtained such results.</p></disp-quote><p>We have added text to the Discussion discussing potential mechanistic differences in 3D versus 2D cultures that cause SOS1 to only synergize with EGFR-TKIs in 3D.</p><disp-quote content-type="editor-comment"><p>7) They used one kind of targeting sequences for SOS1 and SOS2. In order to exclude the possibility of off-target effects, please perform single-cell cloning to have several clones or generate several knockout cells by using at least 2 kinds of targeting sequences. If you have these data please add. If not, please be clear in the paper.</p></disp-quote><p>We appreciate the comment and have updated the Materials and methods and the figure legend to clarify our findings. Indeed, we did use only one targeting vector for each, however, all of our experiments are done in pooled cell populations and not in ‘cell clones’. Whenever possible, we try to avoid using clones in the lab as they can show high variability in responsiveness that is not due to the biology being studied (in this case, SOS1 or SOS2). Instead, having a population of cells gives much more representative data. Also, each experiment where CRISPR was used to delete <italic>SOS1</italic> or <italic>SOS2</italic> was performed at least three independent times (three different infections with CRISPR virus on different dates). We have now made this clear in the manuscript.</p><disp-quote content-type="editor-comment"><p>8) Do disparate 3D spheroid (and organoid) culture systems exist? If so, please briefly summarize the 3D spheroid methodology and rationale, including pros and cons relative to other 3D culture techniques, in the Results section. Alternatively, if one uniform 3D culture technique is consistently used for human NSCLC cell line studies, please explain in detail.</p></disp-quote><p>We appreciate the comment. Indeed, although the method of spheroid culture we use is the most common (and easiest), there are several different methods of spheroid cultures. We have summarized these in the Discussion.</p><disp-quote content-type="editor-comment"><p>9) In the Discussion, please address limitations of the current study and future directions. For example, SOS1 inhibitor, BAY-293 is not suitable for in vivo studies, and the authors should be transparent about that limitation and suggest future directions accordingly. In the absence of animal studies, it is important to describe whether in vivo model studies are necessary for translational and clinical development of the proposed treatment strategy, including discussion within the context of the discussed clinical trials (Discussion, last paragraph).</p></disp-quote><p>We thank the reviewer for this comment and agree with the premise. This comment is in line with comments # 2 and #5 asking for in vivo studies. We have expanded our discussion of the limitations of BAY-293 for in situ studies only, and have expanded our discussion regarding the new Boehringer Ingelheim inhibitors provisionally accepted at Cancer Discovery.</p><disp-quote content-type="editor-comment"><p>10) The study lacks direct evidence that osimertinib and BAY-293 dual therapy prevents EGFR TKI-refractory lung cancer growth. For example, one could envision a study where osimertinib-sensitive cells are continuously treated with osimertinib +/- BAY-293 over time (similar to how EGFR TKI resistant cells are made) to determine whether the addition of BAY-293 delays or prevents osimertinib resistance. Please address.</p></disp-quote><p>We thank the reviewer for the comment, and agree that resistance studies (even in situ) are great experiments to do. We have added a discussion regarding this (and animal studies) future directions in the Discussion.</p><disp-quote content-type="editor-comment"><p>The reported synergy between EGFR inhibition and BAY-293 (but also Shp2 inhibition and BAY-293) and the lack of synergy between EGFR inhibition and targeting of RAF-MEK-ERK or PI3K-AKT is very intriguing and begs the question whether other effector pathways downstream of Ras are engaged (Discussion, fifth paragraph).</p></disp-quote><p>We thank the reviewer for the comment, and have added a discussion about other effector pathways.</p><disp-quote content-type="editor-comment"><p>11) What is lacking here is a RasGTP pull down with BAY-293. Even only one cell line with the nice combo of 2D versus 3D and WT versus SOS1 CRISPR would be very valuable. The drug is still relatively new (2019, PNAS) and some validation would be important.</p></disp-quote><p>We thank the reviewer for the comment, and agree that RAS pulldowns would have rounded out the signaling in Figure 6 nicely. These take time to set up / make CRISPR lines / etc. We have added a discussion of RAS pulldowns and further validation along with the need for resistance and animal studies.</p></body></sub-article></article>